PeerView Clinical Pharmacology CME/CNE/CPE Video cover art

All Episodes

PeerView Clinical Pharmacology CME/CNE/CPE Video — 950 episodes

#
Title
1

Donna A. Culton, MD, PhD - Innovations in Bullous Pemphigoid Management: Targeted Solutions for a Blistering Challenge

2

Chafic Karam, MD / Michelle Kittleson, MD, PhD - All-in for Transthyretin Amyloidosis: Refining Team-Based Approaches to Diagnosis, Treatment, and Lifesaving Patient-Centered Care

3

Jennifer Chan, MD, MPH - Personalized Interventions in Neuroendocrine Tumors: Applying the Latest Systemic Therapy Evidence to Guide Treatment Decisions in Community-Based Settings

4

Yelena Y. Janjigian, MD* - Scaling New Heights in Gastric/GEJ Cancer: Aligning the Evidence on Targeted and Immunotherapeutic Approaches Across the Disease Continuum

5

Shubham Pant, MD - Restructuring Clinical Care Models in Pancreatic Cancer: Expert Guidance on Improving Patient Outcomes With Modern Therapeutic Strategies in Community Settings

6

Hussein Tawbi, MD, PhD - Moving Immunotherapy FORWARD in Melanoma: FOrum on Real-World Applications of Recent Data for Community Practice

7

Beth Sandy, MSN, CRNP, FAPO - Mastering the Breakthroughs in HER2-Mutant NSCLC: Decoding Alterations, Refining Treatment, and Empowering Patients

8

Sara M. Tinsley-Vance, PhD, APRN, AOCN - United for Better Myelofibrosis Care: Nurse–Patient Teamwork for Personalized Delivery of JAKi Standards and Emerging Therapeutics

9

Sagar Lonial, MD, FACP - The MoD Squad in Multiple Myeloma: CELMoDs as New Partners for Innovative Sequential Care in Relapsed/Refractory Disease

10

Jiwon Oh, MD, PhD, FRCPC, Gregory F. Wu, MD, PhD, FAAN - New Pathways, New Possibilities in Multiple Sclerosis: BTK Inhibition and the Future of Patient Care

11

Prof. Nicolas Girard, MD, PhD - Traveling Along the TROP2-Targeted Therapy Pathway in NSCLC: Exploring the Established Role and Expanding Options

12

Laura Klesse, MD, PhD - Building Strong Communities of Care in NF1: Collaborative Strategies and Management Choices With MEK Inhibitors for NF1-PNs Across Age Groups

13

Colleen F. Kelley, MD, MPH - Long-Acting PrEP for Diverse Frontline Providers in an Evolving Prevention Landscape

14

Jordan Mast, MMS, PA-C - Lighting the Way to Patient-Centered Alzheimer’s Care: Employing Amyloid-Targeting Therapies Safely and Effectively Through Careful Patient Selection and Shared Decision-Making

15

Neal D. Shore, MD, FACS - Maximizing NMIBC Outcomes: Personalized, Risk-Adapted Approaches With Intravesical Therapy and Collaborative Care

16

Cedric "Jamie" Rutland, MD - Turning Down the Inflammatory Signal in COPD: Advancing Care With Biologic Therapies Targeting Upstream Cytokines

17

Amy M. Klingler, MS, PA-C, DFAAPA - Keeping Brain Health Top of Mind: Preserving Cognition and Improving Early Detection and Diagnosis of Alzheimer’s Disease

18

Amy Goodrich, CRNP - Patient–Nurse Partnerships in CLL: Making the Most of Targeted Standard of Care Options

19

Unpacking Parkinson's Disease Psychosis: Rapid Detection and Management in Long-Term Care - Unpacking Parkinson's Disease Psychosis: Rapid Detection and Management in Long-Term Care

20

Professor Christopher Chen, Professor Atsushi Iwata, MD, PhD - Strategies for Appropriate Assessment and Use of APOE Status in Alzheimer’s Disease: Clinical Care in the Asia-Pacific Region

21

Christie M. Ballantyne, MD, FACP, FACC - Leveraging Recent Evidence on PCSK9 Inhibition: Strategies to Address Clinical Challenges for Meeting LDL-C Targets

22

David Sabatino, PharmD, BCOP / Marie E. Sirek, PharmD, BCACP, CPP - B-Keepers: Pharmacist Principles for Effective BTK Targeting in CLL, MCL, and Other B-Cell Cancers

23

Prof. Chantal Mathieu, MD, PhD - Betting on Basal Insulin: Improving the Odds for People With Type 2 Diabetes

24

Tanios Bekaii-Saab, MD, FACP, FASCO - Raising the Game in Biliary Cancer: Adapting Rapidly Emerging Evidence and Achieving Optimal Disease Control With FGFR-Targeted Platforms

25

Joyce O'Shaughnessy, MD - Raising the Bar for Survival in High-Risk HR+, HER2- EBC: A Practical Framework for the Adjuvant Setting; Real-World Strategies to Improve Risk Assessment, Candidate Identification, Differentiated CDK4/6i + ET Selection, and Optimal Treatment Delivery

26

Yelena Y. Janjigian, MD*, Marion Liu, MD - Unifying Surgical-Oncology Expertise in Resectable Gastric/GEJ Malignancies: Leveraging the Evidence on Perioperative Immunotherapy Platforms to Deliver Personalized Care

27

Laura S. Dominici, MD, FACS - Lighting the Path in Early Breast Cancer Care: Uniting Evidence, Expertise, and Multidisciplinary Action

28

Hope S. Rugo, MD, FASCO - From Evidence to Impact: Harnessing PI3K/AKT/mTOR Pathway Inhibitors to Improve Outcomes in HR+, HER2- MBC; Shedding Light on Mechanisms, Clinical Evidence, and Adverse Event Management

29

Mrinal Gounder, MD - Paving the Path Forward for Desmoid Tumors: Multidisciplinary Tactics to Effectively Implement Gamma Secretase Inhibitors in Clinical Practice

30

Philip J. Mease, MD, MACR - Targeting Unmet Needs in Psoriatic Arthritis: Cases in Achieving Treatment Goals With TYK2 Inhibition

31

Ellen R. Sher, MD - A Life Less Stuffy for Patients With Perennial Allergic Rhinitis: Exploring Targeted Treatment Approaches to Improve Quality of Life

32

Michael R. Gieske, MD, Nichole T. Tanner, MD, MSCR - Real-World Strategies and Workflows for Lung Cancer Screening Success in Diverse Populations: Enhancing Vigilance to Increase Early Detection on the Front Lines of Care

33

Peter A. Campochiaro, MD / Diana V. Do, MD - Innovations in Retinal Vascular Diseases: Enhancing Patient Outcomes Through Longer-Acting Therapies and Precision Dosing

34

Dana M. Chase, MD, FACOG - Charting New Territories in Endometrial Cancer Care: Insights for Personalizing Treatment With Biomarker-Informed Therapies

35

Brooke E. Howitt, MD / Kathleen N. Moore, MD, MS, FASCO - Pathway to Precision in Ovarian Cancer: A Pathology-Informed Guide to Translating Biomarker Testing Results Into Actionable Treatment With ADCs

36

Heather A. Wakelee, MD, FASCO, Helena A. Yu, MD - Data and Decisions in Advanced NSCLC: Addressing Open Questions to Optimize Immunotherapy and Targeted Options

37

Amit Bar-Or, MD, FRCPC, FAAN, FANA / Tanuja Chitnis, MD, MA, FAAN, FANA - Neuroinflammation in Focus: Interpreting the Latest Evidence for BTK Inhibition in Multiple Sclerosis

38

Juan Fortea, MD, PhD / Professor Frank Jessen, MD - Strategies for Appropriate Assessment and Use of APOE Status in Alzheimer’s Disease: Clinical Care in Europe

39

Barbara Burtness, MD - New Immunotherapy Frontiers in R/M HNSCC: Multidisciplinary Perspectives on Advancing Care in Challenging Patient Populations

40

Cecelia Damask, DO - Building on the Path in CRSwNP: Targeting Upstream Drivers With the Latest Biologic Approaches

41

Robert (Bob) J. Fox, MD, Jiwon Oh, MD, PhD, FRCPC - Disease and Disability Progression in Relapsing MS: Unpacking Efficacy Data to Advance Treatment Decisions

42

Samuel Cytryn, MD / Daniela Molena, MD / Manish A. Shah, MD, FASCO - Synchronizing Success in Resectable Gastric/GEJ Cancer: Merging Expertise to Effectively Deliver Immunotherapy Platforms in the Surgical Setting

43

Seema S. Aceves, MD, PhD - Smoothing the Way in Eosinophilic Esophagitis: Targeted, Team-Based Strategies for Pediatric and Adult Care

44

Aarti Bhatia, MD, MPH / Deborah J. Wong, MD, PhD - Immune Innovation in Head and Neck Cancer: Insights on Checkpoint Inhibitors and Bispecifics Across Disease Settings

45

Toby Maher, MD, MSc, PhD - Rethinking Pulmonary Fibrosis: From Fine-Tuning Diagnosis to Illuminating Novel Pathways for Emerging Treatment Strategies

46

Suzanne E. Schindler, MD, PhD - Preparing for the New Era of Blood-Based Biomarkers in Alzheimer’s Disease: Navigating Guidelines, Understanding Policy, and Integrating Into Practice Workflows

47

Roxana Mehran, MD / Jeffrey Weitz, MD, FRCPC, FRSC, FACP - Navigating the Path to Next-Generation Anticoagulation Strategies: Rising to the Challenge of Unmet Needs in SSP and AF

48

Ana C. Garrido-Castro, MD - TROP2-Targeting ADCs in the Forefront: Changing Standards and Best Practices in TNBC and HR+, HER2- Breast Cancer Care

49

Anju T. Peters, MD, MS, Michael Platt, MD, MSc - Treating With Precision in CRSwNP: Defining the Role of Targeted Biologic Therapy for Optimal Patient Outcomes

50

Thomas Grader-Beck, MD - Sjögren’s Disease and the B-Cell Frontier: What Clinicians Need to Know Now to Prepare for Future Therapies

51

Prof. Kevin J. Harrington, FCRP, FRCR, FRSB, PhD / Prof. Christophe Le Tourneau, MD, PhD - Staying Current on Immunotherapy for HNSCC: Conversations on Clinical Collaboration and Treatment Selection

52

Phillip H. Kuo, MD, PhD / Jonathan E. McConathy, MD, PhD, FSNMMI - Alzheimer’s Disease Case Conference: Building Confidence in Visual Interpretation and Quantitative Analysis of Neuroimaging

53

Simron Singh, MD, MPH - Catalysts for Enhanced Patient CARE In Neuroendocrine Neoplasms: Clinical Adoption of Rapidly Emerging Evidence on Novel Therapeutic Strategies

54

Lauren A. Byers, MD - The ADC Wave in SCLC: Emerging Evidence and Practical Considerations for New Options on the Horizon

55

Prof. Dr. Peter R. Galle - Streamlining Multidirectional Care in HCC: Applying Groundbreaking Evidence on Systemic Treatment Approaches Across the Disease Spectrum

56

Brooke Looney, PharmD, CSP / Alicia K. Morgans, MD, MPH, FASCO - Paving the Path for Optimal Prostate Cancer Care: Preparing Advanced Practice Providers to Integrate Modern Therapies Into Tailored Treatment Plans

57

Nicole Lamanna, MD, Lydia Scarfò, MD - Choices, Changes, and Global Perspectives in CLL Care: Real-World Insights and New Evidence on Finite Therapy With Targeted Agents

58

MeiLan K. Han, MD, MS / Fernando J. Martinez, MD, MS - ECHOing Innovation in COPD: Transforming Patient Care With the Use of Targeted Biologic Therapy

59

Jaume Capdevila, MD, PhD - From Poor Prognosis to Emerging Clinical Potential: A Visual Journey of Targeted Therapy Innovation in Extrapulmonary Neuroendocrine Carcinomas

60

Elizabeth R. Volkmann, MD, MS - Frameworks for Identifying Systemic Sclerosis and Its Complications: From Pathophysiology to Personalized Care

61

Asuncion Mejias, MD, PhD - RSV Prophylaxis Unveiled: What Healthcare Providers Need to Know

62

Benjamin C. Creelan, MD - Taking the High Road in NSCLC: Navigating Through Immunotherapy-Based Treatments to Optimize Outcomes

63

Stephen V. Liu, MD - Innovation Takes the Lead in SCLC: Leveraging Evolving Advances to Drive Improved Outcomes in Limited- and Extensive-Stage Disease

64

Nicola Gökbuget, MD - Moving Forward in B-ALL: Insights on Modern and Emerging Standards With Off-the-Shelf Bispecific Antibodies

65

Prof. Solange Peters, MD, PhD / Prof. David Planchard, MD, PhD - The Challenges of Choice in First-Line EGFRm NSCLC: Practical Guidance on Optimising Treatment Approaches

66

Sia Daneshmand, MD - Elevating NMIBC Care: Putting the Latest Innovations for Intravesical Therapies Into Practice

67

Prof. Eric Van Cutsem, MD, PhD - Precision Tactics With HER2-Targeting ADCs in HER2-Altered Solid Tumors: Candid Conversations and Clinical Consults

68

Komal Jhaveri, MD, FACP - Dialing Up Precision in HR+, HER2- MBC With New Endocrine Agents, Targeted Therapies, and Combinations: A Framework for Multifactorial Clinical Decisions

69

Prof. Dr. Max S. Topp, MD - Off the Shelf and in the Clinic for NHL: Leveraging Bispecific Antibody Strategies in DLBCL, FL, and Beyond

70

Professor John G. Gribben, MD, DSc - Pathways to Personalized Remission in CLL: Leveraging Targeted Standards and Next-Gen Advances for Upfront and Sequential Care

71

David A. Sallman, MD - Menin Masters for AML Care: Guidance on Integrating Menin Inhibitor Regimens and Boosting Efficacy in Challenging AML Subtypes

72

Joyce O'Shaughnessy, MD - Forging New Paths With Earlier Use of ADCs in Breast Cancer: From Clinical Breakthroughs to Improved Outcome

73

Jennifer Woyach, MD - Revealing New Sequences in CLL: Collaborative Care Planning With Real-World Evidence and Modern Therapeutics

74

Zachariah DeFilipp, MD - Rising to the Graft-vs-Host Disease Challenge: Progress in Treatment and Post-HCT Outcomes Across Hematologic Cancers

75

Noel Clarke, MBBS, FRCS ChM / Joaquin Mateo, MD, PhD / Isabela Werneck da Cunha, MD, PhD, MBA - New Kids on the Block in mHSPC: Personalising Approaches Through Emerging Precision Therapies

76

Guillermo Garcia-Manero, MD - MASTER MDS for Enhanced Patient Care: Modern Advances With Standard and Emerging Risk-Adapted Treatment

77

Sagar Lonial, MD, FACP - Many Roads to Myeloma Remission: Making Sequential Choices With BCMA and Non-BCMA Immunotherapies

78

Prof. Dr. Martin Dreyling - Redrawing Frontlines in MCL: The Upfront Expansion of BTKi Options and Modern Clinical Decision-making in Newly Diagnosed Disease

79

Fred Saad, CQ, MD, FRCS, FCAHS - Innovative Approaches in Prostate Cancer: Bridging Genomics and Patient-Centric Treatment

80

Erik Musiek, MD, PhD - Strategies for Appropriate Assessment and Use of APOE Status in Alzheimer’s Disease: Clinical Care in the United States

81

Gary S. Marshall, MD - Prevention at Every Age: A Team-Based Approach to Meningococcal Disease Vaccination for At-Risk Populations

82

Ibiayi Dagogo-Jack, MD, FASCO, Van Karlyle Morris, MD - Calibrating Clinical Approaches for Metastatic Colorectal and Lung Cancers: Insights on Molecular Testing and BRAF Inhibitors in Community Settings

83

Prof. Elisabeth Botelho-Nevers, MD, PhD / Prof. Federico Martinón-Torres, MD, PhD - Shielding Generations With Pneumococcal Vaccination Approaches Across the Lifespan

84

Alireza Atri, MD, PhD, Malaz Boustani, MD, MPH - Implementing Innovation in Alzheimer’s Care: Practical Approaches to Adopting New Diagnostics and Disease-Modifying Treatments

85

Barbara Burtness, MD / Ravindra Uppaluri, MD, PhD, FACS - Definitive Innovation in Resectable Head and Neck Cancer: New Immunotherapy Approaches in LA-HNSCC

86

William D. Tap, MD - Achieving Disease Control in TGCT: Critical Steps For Integrating Evidence-Based Care With CSF1R Inhibitors

87

Gil Rabinovici, MD - Unpacking the Latest Evidence on Biomarkers and ATTs in the Diagnosis and Management of Alzheimer's Disease: Breaking Updates From CTAD 2025

88

Geoffrey Ku, MD - Turning the Tide in Gastric Cancer Management: Integrating Modern Systemic Therapies Across the Disease Continuum for Community-Based Clinicians

89

Thomas Grader-Beck, MD - Beneath the Surface of Sjögren’s Disease: Understanding Systemic Impact and B-Cell–Mediated Pathways

90

Manmeet S. Ahluwalia, MD, MBA, FASCO - Next-Generation Solutions to Optimize Glioma Care: Applying The Latest Evidence on Molecularly Targeted Therapies in IDH-Mutant Disease

91

Scott A. Kaiser, MD / Lisa C. McGuire, PhD, FGSA - Remembering Brain Health: Targeting Modifiable Risk Factors and Early Detection of Cognitive Symptoms to Reduce the Burden of Dementia

92

Milind Desai, MD, MBA, Anjali Tiku Owens, MD - Hypertrophic Cardiomyopathy Care in the CMI Era: Elevating Outcomes With Cardiac Myosin Inhibitors

93

Joseph K. Han, MD, FARS, FAAAAI - Tackling CRSwNP Management With Emerging Biologic Therapies Targeting Epithelial Cytokines: Game On!

94

Prof. Dr. Konstanze Döhner - The Practicalities of Personalised Therapy in AML: The Who, How, When, and Why of Treating IDH1-Mutated Disease

95

Ahmad Masri, MD, MS, Nitasha Sarswat, MD - Contemporary Insights on Diagnosing and Treating Transthyretin Cardiac Amyloidosis: How I Think, How I Treat

96

Christine Franzese, MD, FARS, Flavia C.L. Hoyte, MD, FACAAI - The Type 2 Inflammation Connection in CRSwNP: Optimizing Patient Identification and Targeted Treatments

97

Lynsey P. Teulings, APRN - Ahead of the Immunotherapy Curve in Head and Neck Cancer: Preparing for Expanding Immune Options in Locally Advanced and Recurrent/Metastatic Disease

98

Jay H. Shubrook, DO, FAAFP, FACOFP - Guiding Patients Through Cardio-Renal-Metabolic Conditions: The Essential Role of Primary Care Clinicians

99

Antonio Anzueto, MD / Professor Dave Singh - Addressing an Exacerbating Issue in COPD: Strategies for Individualized Targeted Biologic Therapy to Improve Quality of Life

100

Tatyana Kushner, MD, MSCE, Paul Kwo, MD, AGAF, FACG, FAASLD - Toward Functional Cure in Chronic HBV: Monitoring, Serological Markers, and Evolving Therapy

101

Professor Stephen Johnston, MA, FRCP, PhD - Charting New Paths in the Treatment of ER+, HER2- MBC: Seeking Clarity and Consensus Through Evidence-Aligned Clinical Cases

102

Angela Lamarca, MD, PhD, MSc - The Power of Personalised Approaches in Advanced CCA: Team-Based Strategies to Individualise Clinical Care

103

Susana Banerjee, MBBS, MA, FRCP, PhD, Kathleen N. Moore, MD, MS - Harnessing the Power of ADCs in Gynecologic Cancers: Expert Insights for Practice Integration

104

Philip J. Mease, MD, MACR - Taking a New Look at Psoriatic Arthritis and Its Comorbidities Through the Lens of TYK2 Inhibition

105

David N. Lieberman, MD, PhD - Building Clinical Confidence in the Diagnosis and Multidisciplinary Management of Rett Syndrome

106

Bruce E. Sands, MD, MS - Fibrosis, Flares, and Forward Thinking in Inflammatory Bowel Disease Care: Unlocking the TL1A Axis

107

Professor Julian Gillmore / Mathew S. Maurer, MD - Exploring New Paradigms in Transthyretin Cardiac Amyloidosis Care: Experts vs AI

108

Toby Maher, MD, MSc, PhD - Clearing the Air on Fibrosing ILDs: Pulmonologist Conversations on Timely Diagnosis and Modern Care With Antifibrotic Therapy

109

Yelena Y. Janjigian, MD*, Siva Raja, MD, PhD, FACS - Critical Conversations for Surgeons and Oncologists in Resectable Gastric/GEJ Cancer: Expert Guidance on Integrating Rapidly Evolving Evidence for Immunotherapy Platforms

110

John B. Buse, MD, PhD / Pam R. Taub, MD, FACC, FASPC - To Glycemia and Beyond: Managing Cardiovascular Risk in People With Type 2 Diabetes Using Incretin-Based Therapies

111

Jiwon Oh, MD, PhD, FRCPC - Quiet Progression, Loud Impact in MS: Expert Insights on the Role of BTK Inhibitors Beyond Relapse

112

Prof. Dr. med. Alexander Drzezga - Nuclear Medicine for Alzheimer’s Disease in the Hot Seat: Case Conference on Advancing Early Diagnosis With PET Imaging and Biomarkers

113

Malaz Boustani, MD, MPH, Charles Vega, MD, FAAFP - Brain Health Morning Report: Adapting Primary Care Practice and Workflows to Meet the Needs of an Aging Population

114

April W. Armstrong, MD, MPH - Elevating Psoriasis and Comorbidity Management With TYK2 Inhibition: Achieving and Sustaining Outcomes to Transform Care

115

Prof. Nicolas Girard, MD, PhD / Pasi A. Jänne, MD, PhD - Making Precision Decisions for Patients With EGFRm NSCLC: Success Strategies With Targeted Options, Potent Combinations, and Emerging Agents

116

Michelle Kittleson, MD, PhD - Implementing Targeted Therapies in Transthyretin Cardiac Amyloidosis: From Diagnosis to Stabilization

117

Stuart C. Gordon, MD, FACP, FACG, AGAF, FAASLD - Advancing PBC Care Through Timely Referral and Treatment: From Diagnosis to Long-Term Management

118

Arun J. Sanyal, MBBS, MD - Making Connections to Improve Patient Care in Obesity, Metabolism, and Liver Health

119

Prof. Sanjay Popat, FRCP, PhD - The Earlier the Better in Lung Cancer: Multispecialty Guidance on Screening, Diagnosis and Management of Resectable NSCLC

120

Milind Desai, MD, MBA / Anjali Tiku Owens, MD - Fine-Tuning Hypertrophic Cardiomyopathy Care in the CMI Era: Redefining Management for the Modern Heart Failure Specialist

121

Aleena Banerji, MD - Improving the Care of Hereditary Angioedema: Maximizing Protection With Long-Term Prophylaxis

122

Alexis Ogdie, MD, MSCE, Robert H. Eckel, MD, FAHA, FACC - Tackling Obesity in Psoriatic Arthritis: Key to Better Outcomes and Overall Health

123

Paolo Ghia, MD, PhD - The Clock Strikes Innovation in CLL: Upfront Care With Newer, Time-Limited BTKi Combinations

124

Peter A. Campochiaro, MD - Enhancing Diagnosis and Management of Retinal Diseases in Urgent Care

125

Michelle C. Kaku, MD / Chafic Karam, MD - Targeted Therapy for Hereditary Transthyretin Amyloidosis Polyneuropathy (ATTRv-PN): You Don’t Want to Miss It!

126

Sandeep K. Gupta, MD, AGAF, FACG, FASGE, Jenifer R. Lightdale, MD, MPH - Fast Track to Relief: Accelerating Treatment Initiation and Supporting Patient Follow-Up in Pediatric Eosinophilic Esophagitis

127

Jared R. Brosch, MD - Preparing Your Practice for Amyloid-Directed Therapies in Alzheimer’s Disease: Key Strategies to Enhance Early Diagnosis and Optimize Management

128

Julie R. Brahmer, MD, MSc, FASCO - Maximizing the Potential and Expanding the Impact of Immunotherapy in Advanced NSCLC

129

Komal Jhaveri, MD, FACP - Visual Exploration of the Evolving Role of Novel Oral SERDs, Other ER-Targeting Therapies, and Rational Combinations in ER+, HER2- MBC

130

M. Camille Hoffman, MD, MSc - From Screening Through Treatment: Proactive Engagement of Patients in Team-Based Care for PPD

131

Nitin Jain, MD - Committing to Advances for CLL Care: Conversations on Modern Standards of Care and Next-Gen Innovation

132

Kent E. Vrana, PhD, FAAAS, FASPET - Mastering Cannabinoid Science: Key Insights for Informed Clinical Decision-Making

133

Komal Jhaveri, MD, FACP - Changing the Scenery in ER+, HER2- MBC With New Oral SERDs and Combinations: Foundations, Evidence, and Practicalities

134

Mohammad AZ Al-Ani, MD, FACC, FSCMR - Moving HCM Excellence Into the Fast Lane: Harnessing Technology to Reconfigure Clinical Workflows in an Academic Medical Center

135

Kathleen M. Buchheit, MD, Joseph K. Han, MD, FARS, FAAAAI - Navigating Biologic Therapy in CRSwNP: From Patient Selection to Response Assessment

136

Paul Kwo, MD, AGAF, FACG, FAASLD - The Path to Viral Hepatitis Elimination: Enhancing Screening, Vaccination, Treatment, and Care

137

Jennifer Hsiao, MD - Don’t Miss Hidradenitis Suppurativa: Providing Timely Diagnosis and Management Using Novel Agents

138

Krish Patel, MD - Mapping Therapeutic Directions in DLBCL: Team Strategies for Prognostic Assessment and Implications for Targeted Therapy and Other Innovative Options

139

Jessica Ailani, MD, FAHS, FAAN - From Migraine Recognition to Relief: Improving Outcomes With Patient-Centered CGRP Antagonist Strategies

140

Sarah Cuddy, MD / Ronald Witteles, MD - Expert Perspectives on Novel Approaches to Therapy for ATTR Cardiac Amyloidosis

141

Margaret H. Collins, MD, AGAF, Nirmala Gonsalves, MD, AGAF, FACG - Beyond the Eosinophil: Mastering the Complexities of EoE Diagnosis

142

Jared R. Brosch, MD - Leveraging Biomarkers to Optimize Treatment Outcomes With ATTs in Early Symptomatic Alzheimer’s Disease: New Data and Clinical Pearls From AAIC 2025

143

Sami L. Khella, MD - Targeted Treatments for Transthyretin Amyloidosis: Essential Insights for Neurologists

144

Naval Daver, MD, Ghayas Issa, MD - All Rise for Innovation in AML: Processing New Developments With Menin Inhibitors in Challenging AML Subtypes

145

Grzegorz (Greg) S. Nowakowski, MD, FASCO - Raising Frontline Expectations in DLBCL: Principles for Refining Upfront Treatment and Addressing Unmet Needs With Modern Antibody-Based Combinations

146

Donna D. Catamero, ANP-BC, OCN, CCRC / Joshua Richter, MD, FACP - At the Nexus of Sequential Care in Myeloma: Interprofessional and Patient Perspectives on GPRC5D-Directed Therapies

147

Professor Kausik Ray - Achieving Goals in Lipid Management: Then and Now

148

Ghassan Abou-Alfa, MD, JD, MBA, PhD (hc) - Immune to the Impossible in Hepatobiliary Malignancies: Expert Insights on Breakthrough Innovations for Immunotherapy Platforms in Advanced-Stage Disease

149

Yasmin Mohiuddin, DO / Greg Pontone, MD, MHS - The LEAD Initiative: Launchpad to Excellence in Alzheimer’s Disease: A Quality Improvement Project

150

Jacinda (JAM) Abdul-Mutakabbir, PharmD, MPH / Jewel Mullen, MD, MPH, MPA - Building Confidence in RSV Vaccination: Addressing Vaccine Hesitancy and Inequities in At-Risk Populations

151

David Bernstein, MD, MACG, FAASLD, AGAF, FACP, Steven Flamm, MD, FAASLD, FACG - Transforming PBC Management: Targeted Relief and Improved Outcomes

152

Jonathan L. Kaufman, MD - The Power Sequence in RRMM: Collaborative Approaches for Optimizing Sequential Treatment With Cellular and Off-the-Shelf Immunotherapy

153

Courtney Younglove, MD, FOMA, FACOG, DABOM - Collaborating With Peers to Optimize Obesity Management in Women: Clinical Considerations Before, During, and After Pregnancy

154

Steven R. Feldman, MD, PhD - A New Era in GPP Treatment: Clinical Insights, Biomarkers, and Emerging Therapies

155

Rafael J. Sepulveda, MD, D-ABOM - Beyond Snoring: Diving Into the Spectrum of OSA Screening Tools

156

Jaime Almandoz, MD, MBA, FTOS - Navigating Weight and Sleep: Best Practices for Nonjudgmental Weight Management in OSA Care

157

Sameh Gaballa, MD - Off-the-Shelf and on the Mark in NHL: Strategic Approaches With Bispecific Antibodies and ADCs

158

Hollis Day, MD, MS, MHPE - A Light on the Horizon: Improving Alzheimer's Screening and Diagnosis Through Quality Improvement

159

Professor Jürgen Rockstroh / Dr. Laura Waters - Revisiting HIV Antiretroviral Drug Resistance in the Current Landscape: Expert Insights Into Cause, Consequence, and Clinical Approaches for Management

160

Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO - Leading the Next Chapter of Myeloma Care: Oncology Nurse Stewardship in the Era of Innovative Antibodies and Cellular Therapies

161

Erik Musiek, MD, PhD, Stephen Salloway, MD, MS - AD-SAFE: An Initiative to Build Understanding of ARIA and Skills Needed to Improve Detection and Optimize Response in Specialty Care

162

Caitlin Costello, MD - The BCMA Playbook in Multiple Myeloma: Mastering Sequential Strategies With Bispecific Antibodies and CAR-T Therapy

163

Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, Jennifer Woyach, MD - The Road Ahead for Enhanced Sequential Care in CLL—Updates With Targeted Therapy

164

Prof. Dr. med. Barbara Eichhorst - The Second Coming of Finite Therapy in CLL: Making Informed Treatment Decisions With Newer, Time-Limited BTKi Combinations

165

Shervin Assassi, MD, MS - The Evolving Landscape of Fibrosing Interstitial Lung Diseases: Equipping Clinicians to Enhance Patient Care in the Era of Antifibrotic Therapy

166

Pier Luigi Zinzani, MD, PhD - Upfront Upgrades for Mantle Cell Lymphoma: Integrating the First-Line Use of BTKi Strategies Across Patient Populations

167

Samuel Cytryn, MD, Yelena Y. Janjigian, MD* - Achieving Excellence in Gastric/GEJ Cancer Care: Multidisciplinary Guidance on Immunotherapy Platforms in Resectable Disease

168

Lauren Edgar, DNP, MSN-Ed., RN, FNP - Nursing Strategies in Transthyretin Cardiac Amyloidosis: Targeted Therapies and the Patient Experience

169

Joseph M. Coney, MD, FACS, FASRS - Eye on Equity: A Comprehensive Approach to DR/DME Care in Under-Represented Populations

170

Sagar Lonial, MD, FACP - 4x4 in Multiple Myeloma: Maintaining Momentum for Delivering Innovative Care in Newly Diagnosed and Relapsed Disease

171

Simron Singh, MD, MPH - Treatment Planning Made CLEAR in Neuroendocrine Tumors and Pancreatic Cancer: Personalized Integration of Validated and Emerging Therapies

172

"Prof. Wojciech Jurczak, MD, PhD - Staying on Track Toward Better CLL Outcomes: Delivering Effective Sequential Care Guided by Real-World Experience"

173

Jacob Sands, MD - Tailwinds of Innovation in SCLC: Exploring the Therapeutic Potential of ADCs

174

Prof. Dr. Peter R. Galle - Purpose in Practice for HCC: Delivering Effective Care With Modern Systemic Platforms Across Disease Settings

175

Andres Deik, MD, MSEd, FAAN / Ozlem Goker-Alpan, MD - Cracking the Code of GBA1-Associated Parkinson’s Disease and Lysosomal Storage Disorders: Transforming Diagnosis and Management

176

Elias Jabbour, MD / Ibrahim Aldoss, MD - ALL-in on Bispecific Innovation: Guidance on the Present and Future of Off-the-Shelf Immunotherapy in Acute Lymphoblastic Leukemia

177

Joshua Sabari, MD - Precision Matters in NSCLC: Everything You Need to Know About Biomarker Testing and Targeted Therapies

178

Heinz-Josef Lenz, MD, FACP - Catalysts for Redefined Care in Colorectal Cancer: Adapting Systemic Therapy Regimens Across Disease Settings

179

Zev A. Wainberg, MD - Hope on the Horizon in Gastric Cancer: Breakthroughs in Personalized Care With Immunotherapy and Targeted Strategies

180

Arndt Vogel, MD, PhD - Refining Treatment Models For Biliary Tract Cancer Aligning Practice With Rapidly Evolving Evidence on Immunotherapy and Targeted Platforms

181

Prof. Dr. Patrick Schöffski, MPH / Breelyn A. Wilky, MD - Patient-Centric Frameworks in Desmoid Tumors: Integrating Emerging Science on Gamma Secretase Inhibitors for Progressive Disease

182

Gloria Chiang, MD, Ana M. Franceschi, MD, PhD - Alzheimer’s Disease Neuroradiology Case Conference: Mastering the New Frontier in Diagnosis and Treatment

183

"Adam Friedman, MD, FAAD - Advancing Care for Chronic Spontaneous Urticaria: Navigating an Evolving Treatment Landscape for Optimal Patient Outcomes D"

184

Naval Daver, MD - Winning GAMBITS Against AML: Guidance on Advances and Medical Breakthroughs with Innovative Targeted Strategies

185

Nitin Jain, MD - C3 for CLL: Community Conversations on Modern Care—Implications for Upfront and Sequential Management

186

Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD - Navigating the Layers of Complexity in R/R B-Cell Cancers: From Clinical Prognosis to Emerging Therapeutic Prospects in CLL/SLL, MCL, and DLBCL

187

Hussein Tawbi, MD, PhD - Moving the Efficacy Needle With Immunotherapy in Melanoma: Modern Standards and Next-Gen Strategies in Resectable and Unresectable Disease

188

Sumanta Kumar Pal, MD, FASCO - RCC Treatment Innovations in Practice: Preparing for Individualized Patient Care

189

Karim Fizazi, MD, PhD - Mission Possible in Prostate Cancer: Leveraging Genomics, Modern Therapeutics, and Individualized Patient Care

190

Allison Agwu, MD, ScM, FAAP, FIDSA - Unlocking the Potential of Long-Acting PrEP to Halt HIV Transmissions

191

Michael E. Manning, MD, FAAAAI, FACAAI - From Wheals to Wellness: Transforming Chronic Spontaneous Urticaria Care With Emerging Solutions

192

Tammie L.S. Benzinger, MD, PhD - AD-SAFE: An Initiative to Build Understanding of ARIA and Skills Needed to Improve Detection and Optimize Response in the Emergency Department

193

Jordan Mast, MMS, PA-C - Navigating Advances in Alzheimer’s Disease: Practical Strategies for Integrating New Diagnostic Tools and Amyloid-Targeting Therapies Into Patient Care

194

Anca D. Askanase, MD, MPH / Philip J. Mease, MD, MACR - An Immune Reset for Systemic Lupus Erythematosus: Expanding Therapeutic Horizons With CAR-T Cell Therapy

195

Malaz Boustani, MD, MPH, Charles Vega, MD, FAAFP - Minding Brain Health in the Clinic: Realistic Strategies for Managing an Aging Population

196

Stephen R. Broderick, MD, MPHS - Integrating Immunotherapy in Resectable NSCLC: How to Move From Complexity Toward Clarity

197

Meredith E. Clement, MD - PrEP Personalization in Key Populations: Understanding Unique Needs and Challenges in PrEP Provision

198

Catherine Shu, MD, Gavitt Woodard, MD, FACS - Harnessing Precision With EGFR-Targeted Therapy in Resectable NSCLC: Evidence, Cases, and Considerations for Multidisciplinary Patient Care

199

Gerard A. Silvestri, MD, MS - Facilitating Progress in Early Detection and Intervention in Lung Cancer: Proactive Strategies to Improve Lung Cancer Screening for High-Risk Individuals in VA Healthcare Settings

200

Nathan T. Connell, MD, MPH - Restoring Control in von Willebrand Disease: Collaborative Approaches for Delivering the Right Treatment for the Right Patient at the Right Time

201

Marla Dubinsky, MD / Bruce Sands, MD, MS - Evolving Methods for Precision Care in IBD Management and Targeting TL1A

202

Sharon Cohen, MD, FRCPC, Scott A. Kaiser, MD - AD-SAFE: An Initiative to Build Understanding of ARIA and Skills Needed to Guide Treatment Decisions in Primary Care

203

Sara A. Hurvitz, MD, FACP - From Innovation to Implementation: Unlocking the Full Potential of Antibody-Drug Conjugates in Solid Tumors

204

Sharon J. Sha, MD, MS - Implementing Amyloid-Targeting Treatment for Early AD: Strategies for Overcoming Real-World Challenges

205

Neal D. Shore, MD, FACS - Personalizing Prostate Cancer Care: Real-World Approaches for the Community Urology Practice

206

Tanya Gupta, MD - Navigating the Clinical Integration of TROP2-Targeted ADCs in TNBC and HR+, HER2- Metastatic Breast Cancer: A Customized Learning Journey

207

Christine Franzese, MD, FARS - Biologic Therapy for CRSwNP: Exploring the Advanced Practice Provider’s Role in Patient Care

208

Angela Hirbe, MD, PhD - Bridging Gaps, Shaping Lifelong NF1 Care: Team Strategies and Management Choices With MEK Inhibitors Across the Pediatric-to-Adult Care Continuum

209

Florian Rader, MD, MSc - Taking a Step Forward in HCM Precision Medicine: Aligning Clinical and Managed Care Approaches With New Guidelines, Long-Term Evidence, and Real-World Experience

210

Sara M. Tinsley-Vance, PhD, APRN, AOCN - Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics

211

Prof. Giuseppe Curigliano, MD, PhD - Illuminating a Better Path Forward for HR+, HER2- MBC: Bridging the Science and Art of Medicine in Clinical Decision-Making

212

Jennifer Wargo, MD, MMSc - Unleashing Immunotherapy Against Resectable Melanoma: The Surgeon-Oncologist Alliance for Delivering Adjuvant and Neoadjuvant Therapy

213

Sharon J. Sha, MD, MS - Taking the Lead in Timely Diagnosis of AD: Incorporating Biomarkers Into Routine Patient Care

214

Brenda L. Tesini, MD, Charles Vega, MD, FAAFP - Primary Care at the Center of RSV Prevention: Community-Focused Strategies to Foster Trust and Vaccine Acceptance

215

Amanda S. Cass, PharmD, BCPS, BCOP - DLL3-Targeting BiTE Therapy in SCLC: A Pharmacist’s Guide to Evidence and Integration

216

Jonathan S. Appelbaum, MD, FACP, AAHIVS - Defining and Delivering Person-Centric HIV Care in Key Populations

217

Professor Melanie Davies - Seeing Beyond the Numbers in Type 2 Diabetes: Empowering Patients for Optimal Weight and Glycaemic Management

218

Suzanne Lentzsch, MD, PhD - Starting With a Frontline “Four” in Multiple Myeloma: Case-Based Guidance for Achieving Durable Remissions With Innovative CD38 Antibody Strategies

219

Colleen F. Kelley, MD, MPH - Progressing PrEP: Latest PrEP Advances to Prevent HIV Transmissions

220

Milind Desai, MD, MBA, FACC, FAHA, FESC / Anjali Tiku Owens, MD - Achieving Next-Level HCM Care and Outcomes With Cardiac Myosin Inhibition: From Long-Term Clinical Evidence to Real-World Data

221

Nitin Jain, MD - Time-Limited Innovation for CLL Control: Changing the Treatment Story With Evidence and Emerging Consensus on 1L BTKi -BCL2i Combinations

222

Zachariah DeFilipp, MD, Betty K. Hamilton, MD - The Good, the Bad, and the GVHD: Leveraging Modern Therapeutics to Improve Post-Transplant Outcomes

223

Olalekan Oluwole, MBBS, MPH - Unlocking Efficacy, Expanding Access to CAR-T in Lymphoma and Myeloma: From Practice-Changing Evidence to Real-World and Outpatient Experiences

224

Haydar Frangoul, MD, MS, Julie Kanter, MD - Innovation Takes Shape in SCD: Rewriting Management Principles With Gene Therapy and Revisiting the Role of HCT

225

Anna Chodos, MD, MPH - Brain Health Essentials: Strategies for Adapting Clinical Practice and Workflows to Optimize Cognitive Functioning in an Aging Population

226

Prof. Dr. Selim Corbacioglu / Christine N. Duncan, MD - A Roadmap for Managing Post-HCT VOD/SOS: Team-Based Guidance on Capturing, Assessing, and Managing Diverse Presentations

227

Professor Carel le Roux, MBChB, FRCP, FRCPath, PhD / Donna H. Ryan, MD, FTOS - Adopting Modern Management Strategies for Obesity: Treating the Patient, Not the Disease

228

Courtney R. Arn, APRN-CNP / David M. O’Malley, MD - Navigating the ADC Roadmap for Modern Gynecologic Cancer Treatment: Expert Perspectives on Personalizing Patient Care

229

Krish Patel, MD / Nirav Shah, MD, MS - The Innovation Intersection in B-Cell Cancers: Navigating Choices With Modern Targeted Strategies, Cellular Therapy, and HCT

230

Michael E. Wechsler, MD - Overcoming Challenges in the Management of Severe Asthma: Expert Insights on Emerging Strategies to Close the Gaps to Optimal Care

231

Professor Benjamin Solomon, MBBS, PhD, FRACP, FAHMS - ALK+ mNSCLC Care Compass: Taking Your Best Shot First—Selecting and Sequencing Targeted Therapy and Teaming Up to Achieve Long-Term Success

232

Erika Hamilton, MD - HR+, HER2- EBC: Achieving the Potential of Adjuvant CDK4/6 Inhibition to Reduce Risk of Recurrence

233

Eleonora Lad, MD, PhD - Improving the Patient Experience in Geographic Atrophy: Are You Putting the Latest Advances Into Practice?

234

Anna Kovalszki, MD, FAAAAI, Michael E. Wechsler, MD - Stories Behind the Science in EGPA: Updated Strategies for Diagnosis, Treatment, and Reducing the Steroid Burden in Patients

235

Sophia A. Patel, MD - Mastering the Art of Referring Pediatric Patients With Eosinophilic Esophagitis to Specialty Care for Timely Treatment: Spotting the Signs

236

Robert (Bob) J. Fox, MD / Jiwon Oh, MD, PhD, FRCPC - BTK Inhibition as an MS Treatment Strategy: Targeting Smoldering Neuroinflammation

237

Suzanne E. Schindler, MD, PhD - Integrating Biomarker Testing Into Alzheimer’s Disease Workflows: Tools and Strategies for Specialty Care

238

Hope S. Rugo, MD, FASCO - Securing Equity in Care and Outcomes for Older Patients With HR+, HER2- MBC: Leveraging Patient Assessment, Clinical Evidence, Real-World Experience, and Shared Decision-Making to Individualize Care

239

Jacob Sands, MD - "Experts vs AI" ADC Challenge—Lung Cancer Edition: Interpreting the Evidence, Exploring Practicalities

240

Alireza Atri, MD, PhD, Scott A. Kaiser, MD - Dialing Up the Power of Alzheimer’s Disease Biomarkers: A Practical Pathway to Earlier Diagnosis

241

Maissaa Janbain, MD, MSCR - Leveling the Standard of Care in Hemophilia A: Insights and Strategies for Developing Effective, Personalized Treatment Plans

242

MeiLan K. Han, MD, MS - Expert Insights on the Use of Targeted Biologic Therapy in Patients With COPD and Evidence of Type 2 Inflammation: Taking It on a Case-by-Case Basis

243

Michael Levy, MD, PhD - Navigating MOGAD: Case-Based Insights Into Diagnosis, Treatment, and Management of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

244

Angela Fitch, MD, FACP, FOMA - Breaking Through Biases in Obesity Management: Building Competence, Creating Connections, and Empowering Leaders in Primary Care

245

Erik Musiek, MD, PhD - Visualizing the Role of Neuroinflammation in the Pathophysiology and Management of Alzheimer’s Disease

246

Alicia K. Morgans, MD, MPH, FASCO - Individualizing Prostate Cancer Management: Employing Evidence-Based Strategies to Impact Community Care Across the Disease Continuum

247

David Bernstein, MD, MACG, FAASLD, AGAF, FACP - Innovative Approaches to Manage Primary Biliary Cholangitis: Charting New Courses of Care

248

Sara M. Tolaney, MD, MPH - Elevating Excellence in HR+, HER2- EBC and MBC Care: Success Strategies for Community Oncology Practice

249

Sara A. Hurvitz, MD, FACP - Fine-Tuning the Selection and Sequencing of HER2-Targeting Therapies in HER2-Positive MBC With and Without CNS Metastases: Expert Guidance on How to Individualize Therapy Based on Latest Evidence, Disease Features, Treatment Characteristics, and Patient Needs and Preferences

250

William Kitchens, MD, PhD, FACS, FAST - Improving Kidney Transplant Access and Equity With Innovative Immunosuppression Strategies

251

Gideon M. Hirschfield, MA, MB, BChir, FRCP, PhD - Individualizing the PBC Care Pathway: From Baseline and Beyond

252

Gerald Appel, MD, Dana V. Rizk, MD - Advancements in IgA Nephropathy: Discovering the Potential of Complement Pathway Therapies

253

Grzegorz (Greg) S. Nowakowski, MD, FASCO - Addressing Unmet Needs for Better Outcomes in DLBCL: Leveraging Prognostic Assessment and Off-the-Shelf Immunotherapy Strategies

254

Joshua Sabari, MD - Modern Practice Principles in Lung Cancer—First Find the Targets, Then Treat With Precision: A Concise Guide for Biomarker Testing and EGFR-Targeted Therapy in NSCLC

255

Robert M. Hughes, DO / Christina Y. Weng, MD, MBA - Retinal Disease in Emergency Medicine: Timely Recognition and Referral for Specialty Care

256

Shaji K. Kumar, MD - Restoring Remission in RRMM: Present and Future of Sequential Immunotherapy With GPRC5D-Targeting Options

257

Deborah M. Stephens, DO - From Challenges to Changes in R/R CLL: Forging an Academic-Community Practice Alliance for Effective and Safe Sequential Care

258

R. Scott Turner, MD, PhD / Charles Vega, MD, FAAFP - Diagnose Early, Communicate Clearly: Optimizing Alzheimer’s Outcomes in Primary Care

259

Univ.-Prof. Dr. Peter R. Galle - Elevating Therapeutic Innovation in HCC: Cutting-Edge Strategies Across Disease Settings

260

Heinz-Josef Lenz, MD, FACP - The Personalized Paradigm in CRC Care: Translating Emerging Evidence to Guide Therapy Selection in Advanced Disease

261

Samuel Cytryn, MD - Establishing the Pillars for Precision Care in Gastric/GEJ Cancer: Expert Guidance on Integrating Molecular Screening and Immunotherapy Platforms Across the Disease Continuum

262

John V. Bosso, MD, FAAAAI - Mastering the Art and Science of Biologic Therapy for CRSwNP: Who Are the Candidates and How Do You Manage Their Care?

263

Professor Peter Schmid, FRCP, MD, PhD - Finding the Heat in Cold Tumours: Potential for Perioperative Immunotherapy Strategies in Early Breast Cancer

264

Jessica Donington, MD - Mastering the Integration of Immunotherapy in Resectable NSCLC: Practical Considerations for Real-World Practice

265

Geoffrey Ku, MD - Fortifying the Framework for HER2+ GI Cancers: Precision Treatment Planning With Molecularly Targeted Therapies in GC/GEJC, CRC, and BTC

266

Mara B. Antonoff, MD, FACS / Karen L. Reckamp, MD - Targeting Higher Standards in Resectable NSCLC: The Surgery-Oncology Coalition for Tailoring Care in EGFR and ALK TKI Therapy

267

Joyce O'Shaughnessy, MD - Targeting PIK3CA/AKT1/PTEN and Other Alterations in HR+, HER2- MBC: Navigating the Evidence and Guidance for Use

268

Lucia M. Novak, MSN, ANP-BC, BC-ADM - Individualizing Management Plans for Type 2 Diabetes Through Shared Decision-Making: An Office Hours Activity

269

Prof. Giuseppe Curigliano, MD, PhD - A Recap of Therapeutic Advances in HER2-Positive, HER2-Low, and HER2-Ultralow Breast Cancer: Navigating the Latest Evidence and Maximizing Clinical Impact

270

David R. Spigel, MD, FASCO - Charting a New Course in Limited-Stage SCLC Amid an Immunotherapy Sea Change: Elevating Curative-Intent Treatment Approaches

271

Professor Melanie Davies - Understanding the Individual in Front of You: The Importance of Patient Participation in Weight and Glycaemic Management for People With Type 2 Diabetes

272

Amy J. McMichael, MD - From Roots to Results: Elevating Alopecia Areata Management

273

Vera Bril, BSc, FRCPC, MD - Individualized Treatment for Generalized Myasthenia Gravis: Targeting the Cause and Prioritizing the Patient

274

Kristina M. Deligiannidis, MD - The Future of Care in Postpartum Depression: Comprehensive Strategies for Early Diagnosis and Effective Treatment

275

Milind Desai, MD, MBA, FACC, FAHA, FESC - Remodeling Innovation: Applying Clinical Research and Real-World Experience With Cardiac Myosin Inhibition in HCM and Beyond

276

Michelle Kittleson, MD, PhD / Senthil Selvaraj, MD, MS, MA - Don’t Fail Them Now: Bridging Diagnostic and Treatment Gaps in Transthyretin Cardiac Amyloidosis

277

Professor John G. Gribben, MD, DSc - Crafting Custom Care in CLL: Guidance on Upfront and Sequential Treatment Decisions With Targeted and Immune-Based Platforms

278

Professor Claire Harrison, DM - Mastering the Art of Myelofibrosis Care: Expert Guidance, Clinical Experience, and Innovation for More Personalized Disease Control

279

Guillermo Garcia-Manero, MD - Shifting to Higher Standards in MDS: Custom and Innovative Care to Improve Outcomes for Lower- and Higher-Risk Disease

280

Neal D. Shore, MD, FAC - Navigating Therapeutic Choices in Prostate Cancer: Effective Decision-Making for Patient-Centric Care

281

Marwan Noel Sabbagh, MD, FAAN, FANA - Exploring New Frontiers in Alzheimer’s Disease: Early Detection, Emerging Mechanisms, and Therapeutic Advances

282

Vanita R. Aroda, MD - Intensifying Treatment for Type 2 Diabetes According to Current Guidelines: An Office Hours Activity

283

Stephen V. Liu, MD - Refining the First Strike Against EGFR-Mutated Advanced NSCLC: Personalizing Frontline Treatment Decisions Amid Increasing Complexity

284

Mrinal Gounder, MD - Advancing Therapeutic Control in Desmoid Tumors: Expert Guidance on Modern Diagnostic and Treatment Practices With Gamma Secretase Inhibitors

285

Aaron B. Waxman, MD, PhD - Managing Pulmonary Arterial Hypertension in the Era of Novel and Emerging Treatment Options: It Takes a Village

286

Elena Castro, MD, Karim Fizazi, MD, PhD - What’s Around the Corner in Advanced Prostate Cancer? Candid Conversations to Future Proof Your Practice for Targeted Therapies

287

Nancy S. Reau, MD - Plugging the Gaps in Hepatitis B and C Care: Understanding and Integrating New Guidelines and Advances in Disease Management

288

Manmeet S. Ahluwalia, MD, MBA, FASCO - Capitalizing on Personalized Care in IDH-Mutant Gliomas: Expert Guidance on the Use of Biomarker Testing and Targeted Therapies in Real-World Settings

289

Stephanie Christenson, MD, MAS, Cedric "Jamie" Rutland, MD, FCCP - Targeting a New Approach in COPD: Understanding the Potential Role of Biologic Therapy in Patients With Evidence of Type 2 Inflammation

290

Ira M. Jacobson, MD - In Pursuit of a Functional Cure for Hepatitis B: Monitoring Effectively, Optimizing Treatment, and Reducing Risk of Complications

291

William D. Tap, MD - A Joint Effort to Improve Care in Tenosynovial Giant Cell Tumors: Applying a Collaborative Approach When Integrating Targeted Therapies in Practice

292

Javed Butler, MD, MPH, MBA / Muthiah Vaduganathan, MD, MPH - Experts vs AI: Exploring New Paradigms in Comprehensive Care for Cardio-Renal-Metabolic Diseases

293

Prof. Arjan Bredenoord / Kathryn A. Peterson, MD, MSCI - Improving Care for Pediatric and Adult Patients With Eosinophilic Esophagitis: Expert Insights on the Latest Evidence for Targeted Therapy

294

Sumanta Kumar Pal, MD, FASCO - Smart Steps for Effective Real-World Care in RCC: Enhancing Outcomes in Advanced Disease

295

Chris A. Liacouras, MD - Optimizing Outcomes for Pediatric Patients With EoE: The Importance of Timely Integration of Targeted Biologic Treatment

296

Jason J. Luke, MD, FACP - Resect and Protect Against Melanoma Recurrence: Are You Prepared for the Present and Future of Adjuvant Immunotherapy for Stage II-III Disease?

297

Prof. Dr. med. Alexander Drzezga - Alzheimer’s Disease Case Conference: Acquiring New Skills and Visualizing Emerging Strategies for the Era of Amyloid-Targeting Therapies

298

Kevin Ault, MD, FIDSA, FACOG - The Burden of RSV in Pediatric Populations: Evidence for Reshaping Care and Optimizing Prophylaxis

299

Jennifer Chan, MD, MPH - Renewed Optimism for Personalized Care in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors: The Evolving Role and Clinical Applications of Emerging Strategies to Improve Patient Outcomes

300

Fuad El Rassi, MD, Modupe Idowu, MD - A New Script for SCD Care: Guidance on Patient-Centric Treatment Decisions With Innovative Therapeutics

301

Kathleen M. Buchheit, MD - Uncovering the Role of Epithelial Cytokines in CRSwNP: Examining the Clinical Implications of New Approaches with Targeted Biologic Therapy

302

Andrea Cercek, MD - Accelerating Personalized Care in CRC: The Prominent Role of Predictive Biomarkers and Immunotherapy Platforms in Early and Advanced Disease

303

Surya P. Bhatt, MD, MSPH - Breaking New Ground in the Treatment of COPD: Exploring the Potential Use of Targeted Biologic Therapy in Patients With Evidence of Type 2 Inflammation

304

Meghan C. Thompson, MD - Building Resilient Care Communities for R/R CLL: Collaborative Sequential Approaches in an Era of Innovative Options

305

James F. Howard Jr., MD, FAAN / Nicholas J. Silvestri, MD, FAAN - Steering Away From Steroids in Myasthenia Gravis Management: The Role of FcRn Inhibitors in the Current Treatment Paradigm

306

Guillermo E. Umpierrez, MD, CDE, FACP, FACE - Prioritizing Weight Management as a Primary Goal in People With Type 2 Diabetes: An Office Hours Activity

307

Sharon Cohen, MD, FRCPC / Erik Musiek, MD, PhD - Using APOE as a Key in Alzheimer’s Disease Treatment: Unlocking the Amyloid-Targeting Therapy Risk–Benefit Conundrum

308

Kassandra August-Marcucio, DNP, APRN, ACNP-BC, SANE, Grace Cullen, DNP, FNP-BC, AOCNP, PMGT-BC, FPCN - Nurse-Led Strategies for Optimizing PARP Inhibitors in Veterans With Prostate Cancer: Genomic Testing and Practical Care Delivery

309

Andrew J. Wagner, MD, PhD - Building the Alliance in Dedifferentiated Liposarcoma: Integrating Personalized, Multidisciplinary Care With Innovative MDM2 Antagonists in Advanced Disease

310

Pamela J. McShane, MD - Experts vs AI Challenge: Diagnosing and Managing Nontuberculous Mycobacterial Lung Disease

311

Julie L. Rosenthal, MD, FACC, Ronald Witteles, MD - TTRansforming the TTReatment of ATTR: A Guide to the Pathophysiology, Diagnosis, and Emerging Treatment Strategies for ATTR Amyloidosis

312

Patrick M. Moriarty, MD, FACP, FACC, FNLA, FESC - Changing the Future for Families With HoFH: Long-Term Benefits of Early Diagnosis and Treatment for Homozygous Familial Hypercholesterolemia

313

April W. Armstrong, MD, MPH - Staying on Target Against Moderate to Severe Psoriasis: Strategies for Achieving Sustained Benefits Through TYK2 Inhibition

314

Jessica Donington, MD, Jonathan D. Spicer, MD, PhD, FRCSC - Integrating Immunotherapy in Resectable NSCLC: How to Modify Treatment Trajectories and Reorganize Multidisciplinary Care Pathways

315

Ibiayi Dagogo-Jack, MD / Jay M. Lee, MD - Reinforcing Precision Tactics in Genomically Altered Resectable NSCLC: Collaborative Workflows and Personalized Solutions for Integration of Adjuvant EGFR- and ALK-Targeted Therapies

316

Matthew C. Breeggemann, MD / John C. Lieske, MD - Stepping Stones on the Path to a Healthier Future for Patients With Primary Hyperoxaluria Type 1: Expert Perspectives on Ensuring Timely Diagnosis and Appropriate Management

317

Gil Rabinovici, MD - At the Ready for a New Standard of Alzheimer's Care: Preparing Your Practice for the New Era of Amyloid-Targeting Therapies

318

Professor Stephen Johnston, MA, PhD - How to Make Multifactorial Clinical Decisions in HR+, HER2- EBC and MBC: Guiding Precision Amid Growing Complexity

319

Arndt Vogel, MD, PhD - Strengthening the Immunotherapy Paradigm in Biliary Tract Cancer: Standardizing Team-Based Strategies With Immune Checkpoint Inhibitors in Advanced Disease

320

Dave Singh - Breathing New Life Into Treatment Approaches for COPD: The Latest Insights Into the Role of Type 2 Inflammation and Targeted Biologic Therapy

321

Christopher D. Still, DO, FACP, FTOS - Optimizing Obesity Management Before and After Bariatric Surgery: The Role of Antiobesity Pharmacotherapy to Reduce Weight and Obesity-Related Comorbidities

322

Guillermo Garcia-Manero, MD - Resetting Standards in MDS: New Principles for Integrating Innovative Therapy Into Risk-Adapted Care

323

Stephen Salloway, MD, MS, Sharon J. Sha, MD, MS - Keeping PACE™ in Alzheimer’s Disease: Precision Strategies to Achieve Early Diagnosis and Safely Integrate Disease-Modifying Treatment

324

Taofeek K. Owonikoko, MD, PhD - Taking a BiTE Out of SCLC: Are You Ready for a New Wave of DLL3-Targeting T-Cell Engagers and Other Therapies?

325

Suresh S. Ramalingam, MD, FACP, FASCO - Elevating Expectations, Broadening Impact: How to Leverage Immunotherapy and EGFR-Targeted Therapy to Improve Outcomes in Unresectable Stage III NSCLC

326

William G. Wierda, MD, PhD - Exceeding Expectations in CLL: Workshops on Targeted Standards, Sequential Options, and Emerging Therapeutics for Team-Based Care

327

Stephen V. Liu, MD - Updating the Lung Cancer Treatment Algorithms With Novel Antibody–Drug Conjugates: Are You Prepared for Change? State of the Science, Implications for Practice, and Future Prospects

328

Shannon N. Westin, MD, MPH, Ramez N. Eskander, MD - Rethinking and Refining Endometrial Cancer Care in the Modern Age of Precision Medicine: How to Translate Clinical Evidence Into Meaningful Improvements for Patients

329

Natasha B. Leighl, MD, MMSc, FRCPC, FASCO - Navigating Rapid Changes in First- and Later-Line Treatment of EGFR-Mutated NSCLC: A Practical Framework for Optimal Biomarker Testing, Treatment Selection and Sequencing, and Adverse Event Management

330

Roy S. Herbst, MD, PhD - Elevating Care in Resectable Stage I-III NSCLC: Targeted Therapy and Immunotherapy at the Forefront of Multimodal Treatment Strategies

331

Komal Jhaveri, MD, FACP - Embracing Progress, Transforming Treatment, Empowering Patients: Harnessing the Potential of TROP2-Targeted ADC Therapy in TNBC and HR+, HER2- Breast Cancer

332

Onyema Ogbuagu, MD, FACP, FIDSA - Adjusting HIV Treatment for ART-Experienced People With HIV: Switching ART to Address Antiretroviral Resistance, Adverse Events, and Adherence Barriers

333

Naval Daver, MD, Tapan Kadia, MD - Opportunity Knocks in AML: Guidance on Achieving Truly Personalized Care in Challenging Populations with Modern Therapeutics

334

Prof. Solange Peters, MD, PhD - Are We Closer to a Cure With Perioperative Immunotherapy in Resectable NSCLC? Latest Evidence, Current Conclusions, and Ongoing Questions in Clinical Care

335

Marc S. Sabatine, MD, MPH - Emerging Options for Targeting PCSK9 in Hypercholesterolemia Management: Visualizing New Routes to Individualized Care

336

Stephanie L. Graff, MD, FACP, FASCO - Making Precision Decisions in High-Risk HR+, HER2- Metastatic Breast Cancer: Practical Training on Individualizing CDK4/6 Inhibitor Treatment to Enhance Adherence, Quality of Life, and Outcomes

337

Marwan Noel Sabbagh, MD, FAAN, FANA - From Early Detection to Disease Modification: Personalized Approaches to Biomarker Testing and Therapeutic Management of Alzheimer’s Disease

338

April W. Armstrong, MD, MPH - All Things Considered in Psoriasis Management: Looking at the Role of Biologic Therapies in a Holistic Approach

339

Jacinda (JAM) Abdul-Mutakabbir, PharmD, MPH - Pharmacist-Led RSV Immunization Strategies: Leveraging Trust to Overcome Vaccine Hesitancy

340

Hope S. Rugo, MD, FASCO - Exchanging Ideas on How to Navigate Patient-Centric Clinical Decisions in Integration of TROP2-Targeted Therapy in TNBC and HR+, HER2- Breast Cancer

341

Sara M. Tolaney, MD, MPH - Critically Focusing Decision-Making and Communication Strategies to Reduce Recurrence in High-Risk HR+, HER2- EBC

342

Bradley J. Monk, MD, FACS, FACOG - Advancing Immunotherapy: Revolutionizing Cervical Cancer Treatment

343

John E. Anderson, MD - Conversations With Peers About T2DM: Best Practices for Optimizing Treatment Using Weight Management as a Primary Goal

344

Christopher L. Moertel, MD - Mapping a New Treatment Journey in NF1: New Developments With MEKi for Pediatric and Adult Patients With NF1-Plexiform Neurofibromas

345

Stacey B. Trooskin, MD, PhD, Robert G Gish, MD - A Modern Take on Hepatitis Immunization: Overcoming Today's Hurdles With Recent Guidelines and Practical Strategies

346

P. Barton Duell, MD - Lipid Management Beyond Statins: Early Screening, Prompt Intervention, and Timely Intensification With PCSK9-Targeted Therapies

347

Sharon Cohen, MD, FRCPC - Preparing Specialists for the New Era in Alzheimer’s Disease: A Case-Based Exploration of Strategies for Integrating Diagnostic Biomarkers and Amyloid-Targeting Therapies Into Practice

348

Vanita R. Aroda, MD - Transforming T2DM Treatment in Primary Care: Discerning the Glycemic and Extra-Glycemic Effects of GLP-1 RAs

349

Angela Lamarca, MD, PhD, MSc - Prioritising Patient-Centric Care in Biliary Tract Cancer: Leveraging Immunotherapy Platforms to Overcome Challenges in the Advanced Setting

350

Hussein Tawbi, MD, PhD - Renovating Frontline Care for Metastatic Melanoma: Guidance on Upgrading to Combination Immunotherapy Standards Across Disease Presentations

351

Michael Polydefkis, MD - TTRemendous Advances in Transthyretin Amyloidosis Treatment: What Neurologists Need to Know

352

Praveen Akuthota, MD - Recognizing the Burden of Patients Living With EGPA: An Exploration of Best Practices in Diagnosis and Treatment in the Context of a Multidisciplinary Approach

353

Gil Yosipovitch, MD - The Itch We Could Never Scratch: Incorporating New and Emerging Therapies to Alleviate the Burden of Prurigo Nodularis With a Team-Based Approach

354

Jamy D. Ard, MD, FTOS - Breaking Through Biases: Building Skills for Collaborative Weight Management in Primary Care and Treating Obesity as a Chronic Disease

355

Ticiana Leal, MD - Achieving Optimal SCLC Care With Established and Innovative Therapies: Latest Evidence, Key Ongoing Trials, and Practical Considerations for Real-World Practice

356

Univ.-Prof. Dr. Peter R. Galle - Mastering Multidirectional Tactics in HCC: Expert Guidance on Emerging Trends With Systemic Therapy Options Across the Disease Continuum

357

Hussein Tawbi, MD, PhD / Prof. Christian Blank, MD, PhD - Deploying the Immune GAMBIT Against Melanoma: Guidance on Advances and Medical Breakthroughs With ImmunoTherapy

358

Naval Daver, MD - Unleashing the Innovation Era in AML: Practice Principles and Precision Medicine With Innovative Therapeutics

359

Joyce O’Shaughnessy, MD - Rising to the Challenges of Early and Advanced HR+ Breast Cancer: Examining Complex Evidence to Inform Clinical Decisions

360

Pier Luigi Zinzani, MD, PhD - Stepping Forward to Transform MCL Management: Guidance on the Selection and Use of BTKi Platforms as First-Line Therapy

361

Paolo Ghia, MD, PhD - Opening With Innovation in CLL: The Practicalities and Potential of Finite Therapy With BTKi Platforms

362

Kathleen M. Buchheit, MD / Stella Lee, MD - Precision Learning for Precision Medicine: What You Need to Know About Hitting the Type 2 Target With Biologic Treatment for CRSwNP

363

Benjamin M. Greenberg, MD, MHS - Mastering Diagnosis and Navigating the Sea of Targeted Treatments in NMOSD: Practical Guidance on Optimizing Patient Care

364

Stephen V. Liu, MD - Decoding Biomarker Testing and Targeted Therapy in NSCLC: The Complete Guide for 2024

365

Geoffrey L. Chupp, MD / Autumn Burnette, MD, FACAAI - Leveraging the Power of Targeted Biologic Therapy in Severe Asthma: Do You Know How and For Whom?

366

Barbara Burtness, MD - Progress Meets Innovation in Head and Neck Cancer: Perspectives on Modern Immunotherapy and Novel Therapeutic Mechanisms

367

Mansoor Raza Mirza, MD / Ana Oaknin, MD, PhD - Navigating Recent Advances in Endometrial Carcinoma Treatment: Expert Guidance to Unleash the Power of Immunotherapy and Other Emerging Therapeutic Regimens

368

Sundar Jagannath, MD, FASCO - Extending Innovation From Lymphoma to Myeloma: The Next Wave of Bispecific Antibody Breakthroughs for Clinical Care

369

Peter Voorhees, MD - Three Rs for Modern Myeloma Care: Delivering the Right Treatment for the Right Patient at the Right Time With Antibody and BCMA Platforms

370

Prof. Mohamad Mohty, MD, PhD - Expanding Frontline Frontiers in MM: Insights on Delivering Modern Care With Innovative CD38 Quadruplet Platforms

371

Jaime Almandoz, MD, MBA, FTOS / Safia Khan, MD - Cases in Practice: Prioritizing Weight Loss for People With Sleep Disorders and Overweight/Obesity

372

Stephen Salloway, MD, MS / Sharon J. Sha, MD, MS - Preparing Your Practice for the New Era of Amyloid-Targeting Therapies in Alzheimer's Disease: Expert Insights on Key Evidence, Administrative and Clinical Considerations, and Best Practices for Individualized, Patient-Centered Care

373

Sandip Patel, MD - Illuminating the Path With Immunotherapy for Metastatic, Locally Advanced, and Early-Stage NSCLC: A Guide to Patient Assessment, Treatment Selection, and Multidisciplinary Collaboration Across the Disease Continuum

374

Komal Jhaveri, MD, FACP - Accelerating Therapeutic Progress in HER2+ and HER2-Low Breast Cancer: State of the Science and Guidance for Individualized Clinical Decisions

375

Petros Grivas, MD, PhD - On Target: Integrating Trop-2-Directed Therapeutics for Urothelial Carcinoma With Precision

376

Ruben A. Mesa, MD, FACP - CONTROL Myelofibrosis: Current Options, New Treatment Principles, and Opportunities to Leverage JAKi Platforms and Novel MOAs

377

Andrea Necchi, MD - Candid Conversations on Modern Urothelial Cancer Management: Personalizing Patient Care Using the Latest Evidence and Innovative Therapeutic Strategies

378

Nicole Lamanna, MD - Redefining Frontlines in CLL: Key Questions on the Role of CIT, BTKi Standards, and Innovative BTKi Combinations

379

Manish A. Shah, MD, FASCO - Catalysts for Change in Gastric and GEJ Cancer: Digesting New Evidence and Future Directions of Care With Innovative Immunotherapy and Targeted Platforms

380

Amit Bar-Or, MD, FRCPC / Jiwon Oh, MD, PhD, FRCPC - Taking a Closer Look at Each Patient: Exploring Novel Biomarker and Imaging Strategies in MS

381

Yelena Y. Janjigian, MD - Precision Tactics in HER2-Positive GI Malignancies: Capitalizing on HER2-Targeted Regimens to Improve Outcomes for Gastric/GEJ Cancers, CRC, and BTC

382

Karim Fizazi, MD, PhD - Unlocking the Power of Modern Therapeutic Regimens for Prostate Cancer: Experts Put the Pressure on Key Evidence and Real-World Strategies to Optimize Patient Care

383

William Anderson, MD - Improving Outcomes for Pediatric Patients With Uncontrolled Moderate-to-Severe Asthma Using a Collaborative Approach: Recognition, Referral, and Management in the Era of Targeted Treatment Options

384

Kun "Kevin" Xiang, MD, PhD - Anticoagulation Therapy in NVAF: A Quality Improvement Initiative

385

Safeguarding Patients With HR+, HER2-, High-Risk, Early Breast Cancer: A Practical Roadmap for CDK4/6 Inhibition in the Adjuvant Setting

386

Javier Morales, MD, FACP, FACE - Cases in the Community: Optimizing Treatment and Considering Weight Management as a Primary Goal in People with T2DM

387

Val J. Lowe, MD, Cyrus A. Raji, MD, PhD - Alzheimer’s Disease Case Conference: Gearing Up for the Expanding Role of Neuroradiology in Diagnosis and Treatment

388

Carla M. Nester, MD, MSA, FASN - Aligning Clinical Practice With Emerging Evidence: Navigating the Rapidly Evolving Landscape of Glomerular Kidney Disease Management

389

Monica Gandhi, MD, MPH - Adapting HIV Treatment for People With Substance Use Disorder

390

Rohit Loomba, MD, MHSc - Experts vs AI: Who Is Better at Monitoring and Treating MASLD and MASH?

391

Doreen J. Addrizzo-Harris, MD / Cedric "Jamie" Rutland, MD - Stories Behind the Science in Non-Cystic Fibrosis Bronchiectasis: Understanding Disease Burden, Diagnosing Early, and Looking Toward New Management Options

392

Prof. Mohamad Mohty, MD, PhD / Caitlin Costello, MD - Five Steps for Integrating BCMA Bispecific Innovations: From Clinical Data to Clinical Practice in RRMM

393

Riad Salem, MD, MBA / Mark Yarchoan, MD - Establishing the Collaborative Benchmark for HCC Care: Critical Discussions Between Interventional Radiologists and Oncologists to Maximize Therapeutic Benefit

394

Brett Elicker, MD / David E. Griffith, MD, ATSF, ACCP, OFRSM - Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: Ensuring Prompt Diagnosis Through Accurate Interpretation of CT Imaging

395

Jonathan E. McConathy, MD, PhD / Gil Rabinovici, MD - Applying Advances in PET Imaging to Facilitate the Early Diagnosis of Alzheimer’s Disease: Preparing Nuclear Medicine and Radiology Specialists for New Diagnostic Workflows

396

Sarah Hayward, PharmD, BCOP / Ambar Khan, PharmD, BCOP - A Pharmacist’s Take on Navigating the Expanding Therapeutic Landscape for Endometrial and Cervical Cancers: Insights on Coordinating and Delivering Effective Modern Care

397

Jessica Donington, MD - Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable NSCLC: A Case Exploration of New Standards and Emerging Approaches

398

Suzanne Lentzsch, MD, PhD / Joshua Richter, MD - “Four-Ward” Progress in NDMM: New Developments With CD38 Antibody Quadruplets

399

Nicholas J. Short, MD - Striking Back at ALL: Achieving Lasting Benefits with Bispecific Antibodies and MRD-Guided Strategies Across Disease Settings

400

Sia Daneshmand, MD / Matthew D. Galsky, MD - Modern Team-Based Therapeutic Management for Bladder Cancer Care: Expert Strategies for Integrating the Latest Evidence and Treatment Advances

401

Neal D. Shore, MD, FACS - Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Implementing Modern Therapeutic Advances Across the Disease Continuum

402

Oliver Sartor, MD - On Target: Understanding the Impact of PSMA for Diagnostic and Therapeutic Strategies in Prostate Cancer

403

Sharon Cohen, MD, FRCPC - Specialty Training for the New Era in Alzheimer’s Disease: Building Skills for Making an Early Diagnosis and Implementing Disease-Modifying Treatment

404

Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO - Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remission With Antibodies, BCMA Immunotherapy, and Other Innovations

405

Jamie Carroll, APRN, CNP, MSN - Nurses at the Forefront of Maximizing the Potential of TROP2-Targeted Therapy in TNBC and HR+, HER2- Breast Cancer: Best Practices for Adverse Event Management and Patient Education

406

Marianne Davies, DNP, ACNP, AOCNP, FAAN / Beth Sandy, MSN, CRNP, FAPO - Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices for Patient Education, irAE Management, and Survivorship Care

407

Jonathan A. Bernstein, MD - Chasing the Itch: Exploring the BTK Inhibitor Frontier In Chronic Urticaria

408

Jonathan A. Bernstein, MD - BTK Inhibition Transforming the Landscape of Chronic Spontaneous Urticaria Treatment

409

Milind Desai, MD, MBA, FACC, FAHA, FESC, Andrew Willeford, PharmD, PhD, BCCP - Adapting Managed Care Strategies in the Era of Precision Medicine for Hypertrophic Cardiomyopathy

410

Saakshi Khattri, MBBS, MD, FAAD, FACR - Interdisciplinary Approaches to Management of Immune-Mediated Inflammatory Diseases: Addressing Shared Pathophysiology With JAK Inhibitors

411

Alicia K. Morgans, MD, MPH, Neal D. Shore, MD, FACS - Treatment Advances and Individualized Therapeutic Strategies in Prostate Cancer: Expert Insights on Key Evidence, Practical Tips for Personalized Therapy, and Clinical Integration Approaches

412

Joseph K. Han, MD, Seth J. Isaacs, MD - Biologics in CRSwNP: Putting a Paradigm Shift Into Practice

413

A. Michael Lincoff, MD - Exploring the Evidence: Improving Cardiovascular Outcomes and the Role of Weight Loss Pharmacotherapy

414

Prof. Nicolas Girard, MD, PhD / Aaron Lisberg, MD - Charting a New Path to Better Outcomes With TROP2-Targeting ADCs in Lung Cancer: Unveiling Potential, Shaping Tomorrow

415

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, FASCO - Prescriptions for Successful Myeloma Care: Pharmacy Strategies for Delivering Effective Therapy With Antibody Platform

416

Lecia V. Sequist, MD, MPH - Screening and Early Intervention as the Keys to Success in Lung Cancer: A Practical Approach to Implementing Lung Cancer Screening for High-Risk Individuals

417

Carlos G. Romo, MD, Aimee Sato, MD - Precision and Progress Against NF1: Solutions for Better Outcomes With MEKi and Multimodal Care for NF1 pNF and Other Tumors

418

Olalekan Oluwole, MBBS, MPH - Democratizing the CAR-T Experience: The Principles and Practice of Outpatient Cellular Therapy

419

Laura S. Dominici, MD, FACS - Unraveling the Complex Choices in Early Breast Cancer: A Roadmap to Informed Multidisciplinary Decisions About Assessment and Treatment

420

Lipika Goyal, MD, MPhil / Riad Salem, MD, MBA - The Convergence of Interventional Radiologists and Oncologists in HCC: Shared Decision-Making and Care Coordination at the Center of Personalized Care Across the Disease

421

Richard K. Bogan, MD, FCCP, FAASM - Navigating Narcolepsy in Family Practice: Patient-Centered Strategies to Optimize the Experience and Outcomes of Treatment

422

Jennifer Wargo, MD, MMSc - New Chapters in the Immunotherapy Story for Melanoma: Collaborative Care and Next Steps With Adjuvant and Neoadjuvant Therapy

423

Meghan C. Thompson, MD - From Resistance to Resilience in R/R CLL: Sequencing Strategies for Achieving Effective Continuous Care

424

Kathleen N. Moore, MD, MS - Redefining Endometrial and Ovarian Carcinoma Care: Maximizing the Clinical Potential of Immunotherapy, ADCs, PARP Inhibitors, and Other Emerging Treatment Strategies

425

Bradley J. Monk, MD, FACS, FACOG - Advancing ADCs in Gynecologic Cancers: Expert Insights on Recent Evidence, Implementation Strategies, and Patient Care

426

James E. Galvin, MD, MPH - Navigating Advances in Alzheimer’s Disease: An Expert Consult on Integrating the New Diagnostic Tools and Disease-Modifying Therapies Into Your Clinical Practice

427

Prof. Dr. med. Stephan Stilgenbauer - Finite Therapy, Infinite Possibilities in CLL: Exploring the Rapid Emergence of Newer Time-Limited BTKi Combinations

428

April W. Armstrong, MD, MPH / Jason K. Lee, MD, FRCPC, FAAAAI, FACAAI - Advancing Patient Care in Chronic Spontaneous Urticaria: Reshaping the Future With Targeted Biologic Therapies

429

Javier Morales, MD, FACP, FACE - Conversations With Peers About T2DM: Best Practices for Optimizing Treatment Using Weight Management as a Primary Goal

430

Sergio A. Giralt, MD, FACP - Reinforcing the “Bridge” to HCT in AML: Clinical Conversations on Augmenting Efficacy With Innovative Options as Pre-Transplant and Maintenance Strategies

431

Krina Patel, MD, MSc - Accelerating Remission in Multiple Myeloma: Updates on CAR-T, BCMA Antibodies, and Achieving Deep Responses and Enduring Efficacy

432

Zack DeFilipp, MD - Closing the Treatment Gap in Acute and Chronic GVHD: Improving Post-HCT Outcomes With Innovative Targeted Approaches

433

Roy F. Chemaly, MD, MPH, FIDSA, FACP / Genovefa Papanicolaou, MD, FIDSA, Fellow ASCT - Cracking Down on Post-Transplant CMV: Guidance on Sequential Treatment With Newer Antiviral Agents

434

Prof. Mohamad Mohty, MD, PhD / Christine N. Duncan, MD - Canceling the Cascade of VOD/SOS: Team-Based Prophylaxis, Diagnosis, and Customized Management

435

Sandip Patel, MD - The “Immunosurge” Continues: Moving in Leaps and Bounds to Expand the Role and Impact of Immunotherapy in Metastatic, Locally Advanced, and Early-Stage NSCLC

436

Taofeek K. Owonikoko, MD, PhD - Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic

437

Hussein Tawbi, MD, PhD - Taking the Front Seat in Metastatic Melanoma Care: Guidance on Using PD-1/LAG-3 Platforms as Modern First-Line Options

438

Amy Shapiro, MD - A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations

439

Joshua Sabari, MD - Making Precision Decisions in the Treatment of NSCLC With Common and Uncommon <em>EGFR</em> Mutations: How to Navigate the Expanding Options and Increasing Complexity

440

Benjamin Levy, MD - Peer Pressure: How Well Do You Know Your ADCs? Cracking the Code of Targeted Delivery of Cytotoxic Payloads in Lung Cancer

441

Prof. Laurence Albiges, MD, PhD - Exploring New Routes in Immuno-Oncology: Understanding the Role of Subcutaneous Immune Checkpoint Inhibitors and Preparing for Innovative Delivery Approaches in the Clinic

442

Adam Friedman, MD, FAAD - Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders and the Rationale for Targeted Biologic Therapy: Focus on Moderate to Severe Atopic Dermatitis, Prurigo Nodularis, Chronic Urticaria, and Bullous Pemphigoid

443

Matthew D. Galsky, MD - Making an Impact in Bladder Cancer Care: Integrating the Latest Evidence and Modern Therapeutic Advances Across the Disease Continuum

444

Leonard B. Bacharier, MD - Episode 4: What Are Our Most Significant Challenges in Treating Patients With Moderate to Severe Asthma and What Can We Learn From Each Other?

445

Arzu Yorgancioglu, MD - Episode 3: Uncontrolled Moderate to Severe Asthma in Pediatric and Adult Patients Around the World: Comparing Approaches to Treatment Selection

446

Klaus F. Rabe, MD, PhD, FERS - Episode 2: Which Patients Should Receive Targeted Biologic Therapy and When?

447

Leonard B. Bacharier, MD - Episode 1: Is Your Patient’s Moderate to Severe Asthma Uncontrolled? Global Approaches to Next Steps

448

Reshma L. Mahtani, DO - A Clinical Compass for Selecting and Sequencing HER2-Targeting Therapies in HER2-Positive Metastatic Breast Cancer: An Update on the Latest Evidence, Guidelines, and Expert Insights

449

Benjamin Levy, MD - Leveraging TROP2 Expression in NSCLC: Expert Perspectives on the Present Evidence and Future Potential of TROP2-Targeting ADCs in Lung Cancer Care

450

Alok A. Khorana, MD, FACP, FASCO - REVIVE Initiative: Reinforcing Evidence-Based Principles Against Cancer-Associated Venous Thromboembolism

451

Jerome A. Barakos, MD / Tammie L.S. Benzinger, MD, PhD - Improving the Recognition and Management of Amyloid-Related Imaging Abnormalities (ARIA) in Alzheimer’s Disease Treatment: Practical Tools and Strategies for Radiology and Neuroradiology Specialists

452

Santosh L. Saraf, MD - Activating Better Care in SCD: Guidance on Novel PKR Agents, Other Innovative Therapies, and Modern Care Transitions

453

Nirmala Gonsalves, MD, AGAF, FACG - Timing Matters: Expert Insights on When to Use Targeted Biologic Therapy for Patients With Eosinophilic Esophagitis

454

Robert Dreicer, MD, MS, MACP, FASCO - Doing Better Under Pressure in Prostate Cancer: Key Evidence and Real-World Care Strategies

455

Sumanta Kumar Pal, MD, FASCO - Advancing Personalized Care in RCC: Navigating Rapid Therapeutic Expansion and Sequencing Strategies

456

Kurt A. Schalper, MD, PhD - PATHway to Decoding the Impact of Cancer Immunotherapy: Latest Advances in Biomarker Testing and Pathologic Response Assessment

457

R. Scott Wright, MD - Targeting Elevated Cardiovascular Risk: Current Therapies and New Horizons in Hyperlipidemia Management

458

Joshua B. Wechsler, MD, MSci - Targeting a Brighter Future for Pediatric Patients With Eosinophilic Esophagitis: Ensuring Prompt Diagnosis and Exploring the Role of Biologic Treatment

459

Jessica Donington, MD / Jonathan D. Spicer, MD, PhD, FRCSC - A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant and/or Adjuvant Immunotherapy in Resectable NSCLC

460

Brendon M. Stiles, MD - Building Multidisciplinary Partnerships to Facilitate Genomic Testing and Master the Integration of EGFR-Targeted Therapy in Resectable Stage I-III NSCLC

461

Lipika Goyal, MD, MPhil / Riad Salem, MD, MBA - Synergizing for Success in HCC: Immunotherapy Advances and the Role of the Interventional Radiologist-Oncologist Collaboration Across the Disease Continuum

462

Milind Javle, MD - Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice

463

Erika Hamilton, MD - Simplifying the Complicated: An Algorithmic Guide for Clinical Decision-Making in HR+, HER2- EBC and MBC

464

Erin X. Barrett (Wei), MD - Addressing Unmet Patient Needs in Bullous Pemphigoid: Exploring Targeted Treatment for Safe and Effective Care

465

Ghassan Abou-Alfa, MD, MBA - Calibrating Care Across the HCC Continuum: Guidance on Delivering Effective Care With Modern Immunotherapy and Targeted Approaches

466

Meghan C. Thompson, MD, Catherine C. Coombs, MD - From Resistance to Resilience in R/R CLL: Sequencing Strategies for Achieving Effective Continuous Care

467

Joyce O’Shaughnessy, MD - Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBC

468

Vallerie V. McLaughlin, MD, Ioana R. Preston, MD - Changing Disease Course for Patients With Pulmonary Hypertension: Expert Insights on Improving Diagnosis and Novel Approaches to Treat the Underlying Causes

469

Aditya Bardia, MD, MPH - Revolutionizing Treatment and Equity in HR+/HER2- Early Breast Cancer With CDK4/6 Inhibitors

470

Anjali Tiku Owens, MD - Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes

471

Joshua Sabari, MD - Mastering the Testing for Common and Uncommon EGFR Mutations to Guide EGFR-Targeted Therapy in Advanced NSCLC

472

Vivian G. Oehler, MD - The Sequel to the Targeted Therapy Era in CML: Guidance on Integrating Novel Options Into Cohesive Sequential Care

473

Professor Benjamin Solomon, MBBS, PhD, FRACP, FAHMS - Adapting Our Strategies for Decision-Making in Testing and Treatment of RET-Altered Lung and Thyroid Cancers: A Personalized Learning Journey

474

John L. Marshall, MD - Hitting the Benchmarks in mCRC: A Precision Medicine Quality Initiative for the Care Team

475

Jaffer A. Ajani, MD, FASCO - Looking Beyond the Horizon in Gastroesophageal Cancers: Updated Evidence on How Systemic Therapies Are Redefining Care

476

Prof. John G. Gribben, MD, DSc - Controlling and Conquering CLL: Guidance on Modern Targeted Options, Innovative Combinations, and Sequential Management

477

Fernando J. Martinez, MD, MS - Cracking the Code in COPD: Understanding the Role of Type 2 Inflammation and Potential Clinical Implications of Targeted Treatment

478

Erika Hamilton, MD - Mastering the Art of Precision in the Treatment of HR+ Early and Metastatic Breast Cancer: Risk Assessment, Prognostic Testing, and Selection and Sequencing of Therapies

479

María Díez Campelo, MD, PhD - Exploring Unmarked Territory in MDS: Taking Command and Enhancing Care With Team-Based Diagnosis and Treatment

480

Sergio A. Giralt, MD, FACP and Selina Luger, MD, FRCPC - Achieving Next-Level Care in AML: Conversations on Targeted Platforms, Emerging Immunotherapies, and Implications for Precision Medicine

481

Neal D. Shore, MD, FACS - Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care

482

Amy Shapiro, MD and Prof Pratima Chowdary, MD, FRCPATH- The ‘Clot’ Thickens in the Hemophilia Story: Clinical Perspectives on Enhancing Outcomes With Innovative Non-Factor Therapy

483

Taofeek K. Owonikoko, MD, PhD - Harnessing the Power of the Latest Clinical and Research Advances in SCLC: How to Accelerate Progress and Improve Patient Outcomes With Current and Emerging Therapies

484

Nikhil C. Munshi, MD - Raising the BCMA Standard in Multiple Myeloma: Strategies for Enhanced Care With Potent CAR-T and Bispecific Options

485

Manmeet S. Ahluwalia, MD, MBA, FASCO - Brainstorming New Approaches to Improve Glioblastoma Care: Revolutionary Advances With Modern Gene Fusion–Targeted Therapy

486

Sara A. Hurvitz, MD, FACP - Modern Practice Principles: A Practical “How-To” Guide for Selection, Sequencing, and Optimal Use of HER2-Targeted Therapies in HER2-Positive Breast Cancer

487

Jorge Plutzky, MD - At the Heart of Obesity: Evidence-Based Strategies for Managing Obesity to Reduce Cardiovascular Risks With Weight Loss Pharmacotherapy

488

Shmuel Shoham, MD - Toward a Brighter Future for Preventing COVID-19 in Patients With Hematologic Malignancies: Leveraging the Power of Current Strategies and Next-Generation Agents

489

Jonathan Corren, MD / Mario Castro, MD - Beyond Airway Inflammation: Examining the Potential Clinical Utility of Mucus Plugging and Airway Hyperresponsiveness in Severe Asthma to Assess Severity and Guide Biologic Treatment

490

Professor Chloe Orkin - Getting Personal: Reassessing HIV Management to Better Individualize Treatment Across the Ages

491

Steven Brem, MD - Shattering the Barriers to Glioblastoma Care: Revolutionary Advances With Innovative Technologies and Modern Systemic Approaches

492

April W. Armstrong, MD, MPH / Tina Bhutani, MD, MAS - Staying in the Clear When Managing Psoriasis: Utilizing Biologics to Improve Cutaneous Outcomes in Difficult to Treat Areas, Prevent Psoriatic Disease Progression, and Safeguard Quality of Life

493

Stefano Del Prato, MD - Tools of the Trade: Prioritising Weight Management in People With Type 2 Diabetes – Sharpening Your Skills to Intensify Therapy and Engage in Shared Decision-Making

494

Jonathan I. Silverberg, MD, PhD, MPH - Bridging the Gap to Increased Patient Satisfaction in Moderate to Severe Atopic Dermatitis: Understanding the Role and Clinical Utility of Targeted Therapy

495

Benjamin Levy, MD - Under Pressure to Improve: How to Unlock the Power of Antibody–Drug Conjugates to Transform the Treatment of Lung Cancer

496

Rishi P. Singh, MD, FASRS - Optimizing Real-World Outcomes in Wet AMD: Reducing the Burden of Treatment With Longer-Acting Therapies

497

PD Dr. med. Luc Biedermann - Targeted Biologic Therapy in Eosinophilic Esophagitis: Practical Strategies for a Changing Therapeutic Landscape

498

Matthew A. Gubens, MD, MS, FASCO - Roadmap to Success With Immunotherapy's Dynamic Evolution in Metastatic, Locally Advanced, and Early-Stage NSCLC: Multidisciplinary Best Practices for Exemplary Care

499

Yelena Y. Janjigian, MD - Equitably Empowering Our Upper GI Cancer Patients Using Plain Language Tools to Improve Outcomes With Immunotherapeutic Regimens Through Informed Shared Decision-Making

500

Neal D. Shore, MD, FACS - Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum

501

Robert M. Hughes, DO - Retinal Disease in the ED: “See Me Now”- A Primer for Emergency Physicians on the Recognition and Differential Diagnosis of Retinal Vein Occlusions

502

Sumanta Kumar Pal, MD, FASCO - Leveling Up Our RCC Care Strategy: Real-World Translation of Key Evidence Across Treatment Settings

503

W. Troy Donahoo, MD, FTOS - Obesity as a Chronic Disease: Practicing What We Preach to Overcome Stigma and Inspire Change

504

Bradley J. Monk, MD, FACS, FACOG - The ABCs of ADCs for Gynecologic Cancer: Expert Insights on Effective Implementation and Practical Tips for Use in Patients With Cervical, Ovarian, or Endometrial Cancer

505

Darren McGuire, MD, MHSc - Translating Data Into Practice: Examining the Impact of Weight Loss Pharmacotherapy on Cardiovascular Outcomes

506

Roxana Mehran, MD / Jeffrey Weitz, MD, FRCPC, FRSC, FACP - Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care

507

Thomas G. Martin, III, MD - The A-Team Against Relapsed/Refractory Myeloma: Community Strategies for Enhancing Outcomes With Potent CD38 Antibody Platforms

508

Josep Tabernero, MD, PhD / Shubham Pant, MD - Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care

509

Beth Sandy, MSN, CRNP, FAPO - Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care

510

Dan Atkins, MD - Facing the Challenges of EoE Head On: A Game Plan for Diagnosis and Integrating Targeted Therapy Using a Team Approach

511

Javier Morales, MD, FACP, FACE / Jay H. Shubrook, DO, FAAFP, FACOFP - Cases in the Community: Optimizing Treatment and Considering Weight Management as a Primary Goal in People With T2DM

512

Mrinal Gounder, MD - Getting to Know the New Desmoid Tumor ICD-10-CM Codes and Why They Matter: Practical Guidance for Integrating the New Codes and Navigating the Implications

513

James F. Howard Jr., MD - FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application

514

James D. Berry, MD, MPH - Making the Most of Advances in Amyotrophic Lateral Sclerosis: Strategies to Improve Early Diagnosis and Maximize the Benefit of Novel Treatment Options

515

Paolo Tarantino, MD - Revolutionizing Solid Tumor Treatment, Unleashing the Potential of Antibody–Drug Conjugates: How to Make the Most of the Latest Clinical Evidence to Enhance Patient Care

516

Eric Marsh, MD, PhD - Honing Diagnostic and Management Skills: The Role of the Pediatrician in the New Era of Rett Syndrome Management

517

Nirav Shah, MD, MS / Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD - Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R Disease

518

April W. Armstrong, MD, MPH / Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP - Finding the Right Pathway in Psoriasis: New Insights and Applications for TYK2 as a Therapeutic Target in Real-World Practice

519

Amy S. Paller, MD - Clearing the Way for Pediatric Patients of All Races With Moderate to Severe Atopic Dermatitis: Expert Perspectives on Identifying and Assessing Disease Severity and Implementing Targeted Treatment

520

Alan K. Percy, MD - From Early Recognition to Age- and Stage-Appropriate Care: Navigating a New Era in Rett Syndrome Management

521

Luke Maese, DO - Making Choices, Improving Outcomes in Pediatric ALL: The Role of Modern Asparaginase Compounds

522

Claudia A. Chiriboga, MD, MPH, FAAN - Building a Better Bridge: Providing Continuous SMA Care From Adolescence Through Adulthood

523

Philip J. Mease, MD, MACR - Diagnosing and Managing Axial Spondyloarthritis: The Role of the Primary Care Clinician in Multidisciplinary Care

524

Milind Desai, MD, MBA - Following the Evolution of Cardiac Myosin Inhibition: Remodeling Clinical Workflows to Realize the Greatest Benefit in oHCM and Beyond

525

Truman J. Milling Jr., MD, FACEP - Reversal of Misfortune: Practical Insights for Managing Uncontrolled FXa-Inhibitor–Related Bleeding

526

John C. Byrd, MD - Choosing Wisely, Achieving Control With BTKi in CLL: Perspectives on Safety-Informed Approaches to Enhanced Therapeutic Efficacy

527

Hiddo J.L. Heerspink, PhD, PharmD / Prof. Dr. med Christoph Wanner - Chronic Kidney Disease in Patients With Type 2 Diabetes: The Impetus for Early Recognition and Strategies for Coordinating Optimal, Patient-Centered Care

528

Ticiana Leal, MD - Optimizing the Care of Patients With SCLC in the Community Setting: How to Make the Most of the Latest Therapeutic Advances and Team-Based Best Practices

529

Josh Hamilton, DNP, RN/PMH-BC, FNP-C, PMHNP-BC, CTMH, CNE, CLNC, FAANP / Rhone D'Errico, DNP, MBA, APRN, FNP-BC, PMHNP-BC, ENP-C, CNE, ACUE - Realizing the Potential of Rapid-Acting Treatments for Depression: Key Clinical Evidence, Practical Considerations, and Best Practices for Individualized, Patient-Centered Care

530

Reynold A. Panettieri, Jr., MD - Expert Perspectives on Improving Early Recognition and Treatment of COPD With Inhalation Therapy

531

Seema S. Aceves, MD, PhD - Living With Eosinophilic Esophagitis: Recognizing the Burden on Patients and Integrating Targeted Therapy to Improve Outcomes

532

Anjali Tiku Owens, MD - Removing Obstructions for Improved HCM Care: Leveling Up Diagnosis and Management in General Cardiology Practice

533

Jessica Donington, MD - Unleashing the Potential of Perioperative Immunotherapy in Resectable NSCLC: Leveraging Science, Enhancing Collaboration, and Improving Outcomes With Neoadjuvant and/or Adjuvant Checkpoint Inhibition

534

Michael R. Savona, MD / Andrew M. Brunner, MD - Command and Control MDS: New Science in MDS Management and Implications for Veteran-Centered Care

535

Naval Daver, MD - Expanding the Circle of Personalized AML Treatment: Expert Consults on Integrating Precision Medicine With Innovative Treatment Platforms

536

Stephen V. Liu, MD - A Bold Frontier: Shattering the Limits of Conventional Therapies and Reshaping the Future of Lung Cancer Treatment With TROP2-Targeting ADCs and Rational Combinations

537

Melissa L. Johnson, MD - Taking Aim With the Next Wave of Antibody–Drug Conjugates in NSCLC: Rational Strategies for Addressing the Unmet Needs of Diverse Patient Populations With TROP2- and HER3-Targeting Therapies and Other ADC-Based Regimens

538

Sagar Lonial, MD, FACP, Krina Patel, MD, MSc - Setting New Expectations in Multiple Myeloma: Guidance on BCMA CAR-T and Antibody Options to Enhance Patient Care

539

William G. Wierda, MD, PhD, Nicole Lamanna, MD - Level Up With Personalized Care for CLL/SLL: Achieving Better Total Care With Targeted Agents and Innovative Combinations

540

Guillermo Garcia-Manero, MD / Amy E. DeZern, MD, MHS - The Commanding Heights of MDS Care: Team Strategies for Delivering Modern Personalized Therapy

541

Stacy E. Croteau, MD, MMS, Steven W. Pipe, MD - Expert Insights on Optimizing Patient Outcomes With Novel EHL FVIII Strategies in Hemophilia A

542

Jaime Almandoz, MD, MBA, FTOS - Leading the Charge to Change the Obesity Narrative: Supporting Primary Care to Improve Weight Management Discussions, Diagnosis, and Decisions

543

Boni Elizabeth Elewski, MD, Mark Lebwohl, MD - Novel Targets for Management of Generalized Pustular Psoriasis: Utilizing a Team-Based Approach From Diagnosis to Treatment of Flares

544

Richard Keen, PhD, FRCP, Edna E. Mancilla, MD - Can YOU Avoid Iatrogenic Harm? Understanding and Identifying Fibrodysplasia Ossificans Progressiva

545

Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP / Peter A. Lio, MD - Targeting Interleukins to Improve Treatment Outcomes in Atopic Dermatitis

546

Kara Mayes, MD, FAAFP / Jay H. Shubrook, DO, FAAFP, FACOFP - Now Is the Time to Overcome Therapeutic Inertia in T2D to Achieve Personalized Glycemic and Weight Management Goals

547

R. Scott Wright, MD - When Statins Strike Out: Using PCSK9-Targeting Strategies to Achieve Lipid Goals and Reduce Cardiovascular Risks in Patients With Hyperlipidemia

548

Stephen P. Salloway, MD, MS - Case by Case: Actioning Patient-Centered Strategies for Risk Assessment, Diagnosis, and Management of Amyloid-Related Imaging Abnormalities (ARIA)

549

David J. Kuter, MD, DPhil / Cindy Neunert, MD, MSCS - New Rules for Overcoming ITP: Guidance on Later-Line Care, the Role of BTKi, and Improving Patient Outcomes

550

Jennifer Woyach, MD - Taking Direction From Biomarkers and Prognostic Factors in CLL: Interprofessional Strategies for Addressing Challenges With Continuous BTKi Therapy

551

Alexander Drilon, MD - Selective, Potent, Different: How to Enhance Clinical Benefits With Next-Generation ROS1 and TRK Inhibition in Treatment-Naïve and Pretreated NSCLC and Other Tumors

552

Mark J. Levis, MD, PhD - Finding the Key to Better Outcomes in FLT3-Mutated AML: Guidance on New Evidence With Next-Gen FLT3 Inhibitors

553

Bradley S. Miller, MD, PhD - Improving Outcomes in Pediatric Growth Hormone Deficiency With Effective Diagnosis and Personalized Management Strategies

554

Ruben A. Mesa, MD, FACP - Taking the Targeted Option for Myelofibrosis: Insights on Modern JAKi Platforms and Emerging Therapeutics

555

Philip Harvey, PhD - Visualizing a New Horizon: Emerging Advances in the Treatment of Cognitive Impairment Associated With Schizophrenia

556

Vanita R. Aroda, MD - Leveraging Early GLP-1 RA Initiation to Reduce Risks and Improve Long-Term Outcomes in Patients With T2DM

557

Steven W. Pipe, MD - Leading the Change in Hemophilia A: Guidance on Enhancing Prophylactic Care With Innovative EHL FVIII Products

558

Pasi A. Jänne, MD, PhD - A Visual Exploration of New Targeted Therapies for EGFR Exon 20 Insertions in NSCLC: The Latest Evidence and Practical Guidance for Biomarker Testing and Individualized Treatment Selection and Sequencing

559

Ilya M. Nasrallah, MD, PhD - Navigating the New Era of Molecularly Defined Care in Alzheimer’s Disease: Applying Nuclear Medicine to Quantify Neuropathology and Improve Diagnostic Accuracy in the Earliest Stages of the AD Continuum

560

Prof. Thomas Cluzeau, MD, PhD - “Intensity” With Efficacy in Acute Myeloid Leukemia (AML): Developing Modern, Intensive Upfront Platforms for Challenging Disease Presentations

561

Prof. Dr. Martin Dreyling - Taking the Leap in MCL: New Opportunities With BTK Inhibitors and Other Innovative Strategies

562

Stephen V. Liu, MD - Amplifying the ADC Advantage: How to Fulfill the Potential of Antibody–Drug Conjugates as the Next Frontier in Precision Lung Cancer Care

563

Rohit Loomba, MD, MHSc - Hope Is on the Horizon for Nonalcoholic Steatohepatitis: Leveraging the Power of Next Generation Monitoring and Pharmacotherapies

564

Guillermo Garcia-Manero, MD - The Team Takes Command in MDS: Guidance on Diagnostic and Treatment Principles for Risk-Based Care and Beyond

565

Robert Z. Orlowski, MD, PhD - The New ABCs of Myeloma Care: Enhancing Outcomes With CD38 Antibodies, BCMA Immunotherapy, and Unique Bispecific Platforms

566

Allison Agwu, MD, ScM, FAAP, FIDSA - Retaining and Re-Engaging People Living With HIV in Care: A Unique Look at Challenges and Opportunities From the Perspective of the Patient, Navigator, and Provider

567

Martina J. Porter, MD - How Do You Diagnose and Treat Hidradenitis Suppurativa? Compare Your Approach With the Experts’

568

Naval Daver, MD - Pushing Innovation in AML: Real-World Integration of Modern Therapeutics Into Personalized Patient Management

569

Ghassan Abou-Alfa, MD, MBA - Renovating the Clinical Rulebook for HCC: Multidirectional Management With Innovative Immunotherapy and Targeted Platforms

570

John B. Buse, MD, PhD - Scoring Comprehensive T2DM Management Goals: Examining the Multifaceted Effects of GLP-1 Receptor Agonists

571

Amit Bar-Or, MD, FRCPC - Can a Novel DMT Class Deliver Better Outcomes in MS? Considering the Potential of BTK Inhibition

572

P. Barton Duell, MD - Straight From the Experts: Clinical Conversations on Modernizing Hyperlipidemia Management With PCSK9-Targeting Agents

573

Sumanta Kumar Pal, MD, FASCO - Fine-Tuning the Wave of Innovation in RCC: Personalized Management Across the Disease Spectrum

574

David M. O'Malley, MD - Endometrial Cancer Care in the Age of Immunotherapy: Translating Clinical Evidence Into Meaningful Improvements in Patient Outcomes Across the Disease Continuum

575

Jiwon Oh, MD, PhD, FRCPC - New and Emerging Biomarkers in Patient-Centered MS Management: The Future of Personalized Patient Care Begins Now

576

Juan Pablo Frías, MD - Case in Point: Addressing Practical Questions to Improve Long-Term Outcomes in Patients With Obesity

577

Charles L. Daley, MD - Improving Time to Diagnosis of Non-Cystic Fibrosis Bronchiectasis: The Importance of the Radiologist in Fulfilling Unmet Needs of Patients

578

Clinical Pharmacology

579

Taofeek K. Owonikoko, MD, PhD - Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making the Most of Current Standard-of-Care Therapies and Exploring New Promising Research

580

Matthew S. Davids, MD, MMSc - Defying the Odds With Innovation in CLL: Perspectives on Personalized Care, Multiagent Platforms, and Sequential Strategies

581

Jason J. Luke, MD, FACP - Immunotherapy for the Win Against Melanoma: Strategies for Integrating Innovative and Next-Generation Immunotherapy Options

582

Shmuel Shoham, MD / Ghady Haidar, MD - What’s New, and What’s Next? Customizing COVID-19 Prevention Approaches in Transplant Patients to Increase Uptake, Access, and Efficacy

583

Barbara Burtness, MD - Building on the Immunotherapy Foundation for Head and Neck Cancer: Lessons Learned, Practical Guidance, and Next Steps in Care

584

Benjamin M. Brucker, MD - Can We Improve Management of Overactive Bladder in Long-Term Care? Examining the Role of Beta-3 Adrenergic Agonists

585

Elena Elimova, MD, M.Sc., FRcPC - Polishing Management Protocols in HER2-Expressing GI Cancers With Targeted Agents: A Focus on Refining Team-Based Strategies to Individualize BTC and GEA Care

586

Athena Philis-Tsimikas, MD - Episode 1: Current Guidance and Indications for Basal Insulin in Patients With T2DM

587

Athena Philis-Tsimikas, MD - Episode 2: Overcoming Clinical Inertia in Patients With T2DM

588

Athena Philis-Tsimikas, MD - Episode 3: Practical Considerations for Once-Weekly Basal Insulin Therapy

589

Athena Philis-Tsimikas, MD - Episode 4: Exploring Therapeutic Potential of Once-Weekly Basal Insulin Therapy

590

Jessica Ailani, MD, FAHS, FAAN, FANA - Breakthrough Therapies for the Prevention and Acute Treatment of Migraine: Addressing Unmet Needs in the Primary Care Setting

591

Luke Maese, DO, Rachel Rau, MD - Building a Foundation for Enhanced Outcomes in Pediatric ALL: Guidance on the Asparaginase Component of Modern Therapy

592

Jaime Almandoz, MD, MBA, FTOS - Practicing What We Preach: Your Role as an Obesity Medicine Specialist, Inspiring Change, and Overcoming Negative Weight Biases to Prioritize the Management of Obesity as a Chronic Disease

593

Brett Elicker, MD - Taking a Look Ahead in Non–Cystic Fibrosis Bronchiectasis: Leveraging Early Diagnosis and Emerging Therapies to Improve Quality of Life

594

Kimberly Halla, MSN, FNP-C - Expert Nursing Insights on Personalized Care for Gynecologic Cancers: Educating and Supporting Patients on the Latest Therapeutic Approaches

595

Laura Klesse, MD, PhD / Carlos G. Romo, MD - The Bedrock of Personalized NF1 Care: Fundamentals of Managing NF1-Associated PNs and Other Tumors With Innovative Targeted Therapy

596

Miguel Regueiro, MD - Taking Fuel From the IBD Fire: Applying New Evidence on Sphingosine-1-Phosphate Receptor Modulation as an Effective Oral Option for Management of Ulcerative Colitis

597

Catherine Shu, MD / Brendon M. Stiles, MD - Bringing Precision Lung Cancer Care to the Perioperative Space: How to Maximize the Impact of EGFR-Targeted Therapy in Resectable NSCLC

598

Jonathan D. Spicer, MD, PhD, FRCSC - Neoadjuvant, Adjuvant, or Both: How to Solve the Puzzle of Perioperative Immunotherapy, Individualize Treatment Plans, and Improve Cure Rates in Resectable NSCLC

599

Marianne Davies, DNP, ACNP, AOCNP, FAAN - Nurses at the Forefront of the Continuing Success Story of Immunotherapy in NSCLC: Best Practices for Guiding and Supporting Patients Through Treatment and Survivorship

600

Brenda Martone, MSN, ANP-BC, AOCNP - Meeting Patient Needs Through Optimal Nursing Strategies in Personalized Bladder Cancer Care

601

Brooks D. Cash, MD, FACP, FACG, FASGE, AGAF, RFF - Addressing Unmet Nursing Needs in the Management of IBS-C: Understanding the Mechanism of Disease, Newer Therapies, and Coordinated Approaches to Treatment Barriers

602

Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO - Betting on BCMA in Multiple Myeloma: Oncology Nurse Principles for Delivering Effective Care With BCMA Antibodies and Cellular Therapy

603

Patrick A. Flume, MD / Gwen A. Huitt, MD, MS - Improving the Patient Experience in Nontuberculous Mycobacterial Lung Disease: The Intersection of Early Diagnosis, Customized Therapy, and Adverse Event Management

604

Anna Chodos, MD, MPH - Facilitating Cognitive Assessment in Primary Care for the Timely Detection of Alzheimer’s Disease: Leveraging Medicare Reimbursement Mechanisms to Improve Clinical Care

605

Laura J. Zitella, MS, RN, ACNP-BC, AOCN - Leading Change, Leading Advances in CLL Care: Guidance on Delivering Modern Targeted and Cellular Therapeutics

606

Linda R. Duska, MD, MPH / Debra L. Richardson, MD, FACS, FACOG - Upgrading the Treatment Algorithm for Advanced Ovarian Cancer: Expert Tips, Tools, and Patient Care Strategies for Making the Most of PARP Inhibitors Across the Disease Continuum

607

Daniel S. Reich, MD, PhD - Targeting BTK: The Latest Data on the Evolving Treatment Landscape for Patients With MS

608

Vera Bril, BSc, FRCPC, MD - Leveraging FcRn Modulation in Personalized Management of Generalized Myasthenia Gravis: Applying the Evidence, Tools, and Patient Perspectives to Achieve Treatment Goals

609

Stanley C. Jordan, MD, FASN, FAST - Visualizing Progress in the Treatment of Chronic Active Antibody-Mediated Rejection: A Closer Look at the Clinical Potential of Targeting IL-6 to Improve Outcomes in the Kidney Transplant Setting

610

Nicholas K. Mollanazar, MD, MBA - Targeting Disease Pathophysiology to Achieve Effective Treatment in Prurigo Nodularis

611

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, Zahra Mahmoudjafari, PharmD, MBA, BCOP - Coordinating Better Outcomes in Multiple Myeloma: Pharmacist Leadership With Novel Antibodies and CAR-T Therapy

612

Monica Tang, MD - Pulling the Plug on Severe Asthma: Taking a Closer Look at an Underrecognized Biomarker to Assess Disease Severity and Tailor Treatment

613

Stuart J. Schnitt, MD - A New View of the Spectrum of HER2 Expression and Significance of HER2 Low in Breast Cancer: Exploring the Biology and Updating Best Practices for Testing and Treatment

614

Laura J. Zitella, MS, RN, ACNP-BC, AOCN - Real-World Nursing Solutions for AML Care: Insights on the Effective and Safe Delivery of Innovative Therapeutics

615

Emily K. Dotson, PharmD, BCOP - Crafting the New Treatment Mix in CLL: Pharmacist Insights on Delivering Effective Care With Targeted Therapy

616

David M. O'Malley, MD - Immunotherapy as a Treatment Cornerstone for Advanced Endometrial Cancer: Personalizing Patient Care

617

Laura S. Dominici, MD, FACS - Navigating Complex Decisions at the Intersection of Local and Systemic Management of Early Breast Cancer

618

Jennifer Wargo, MD, MMSc - Harnessing the Power of Immunotherapy in Resectable Melanoma: Guidance for Delivering Effective Adjuvant and Neoadjuvant Strategies

619

Natasha B. Leighl, MD, MMSc, FRCPC, FASCO - Refining Precision Decisions in NSCLC With Common and Less Common EGFR Mutations: Navigating Testing and Treatment Throughout the Disease Continuum

620

Hyman Scott, MD, MPH, David Alain Wohl, MD - Exchanging PrEP Insights: Clinical Expert and Patient Perspectives on How to Become a Trusted HIV Prevention–Certified Provider

621

Sarina B. Elmariah, MD, PhD, MPH, Shawn Kwatra, MD - Moving Beyond Off-Label Management in Prurigo Nodularis: Exploring New Treatment Options

622

Matthew D. Galsky, MD, Neal D. Shore, MD, FACS - The New Immuno-Oncology Era in Early-Stage Bladder Cancer: Readying the Modern Urology Practice

623

Rami Komrokji, MD - Seizing the Precision Care Moment in MDS: Collaborative Strategies for Accurate Diagnoses and Risk-Adapted Treatment

624

Naval Daver, MD, Joseph D. Khoury, MD, FCAP - The Precision Team in AML: Exploring Pathologist-Informed Clinical Decisions in Challenging AML Settings

625

Saira Z. Sheikh, MD, FAAAAI, FACAAI, FACR, Brad Rovin, MD, FASN, FACP - Improving the Patient Experience in SLE and LN: The Intersection of Early Diagnosis, Individualized Treatment, and Culturally Competent Care

626

Riad Salem, MD, MBA, Mark Yarchoan, MD - Essential Conversations for HCC: Radiology-Oncology Collaboration and Immunotherapy Advances in Intermediate and Advanced Disease

627

Tricia Cottrell, MD, PhD, Lynette M. Sholl, MD - Gaining Confidence in Predicting and Assessing Response to Cancer Immunotherapies: Practical Strategies for Biomarker Testing and Pathologic Response Assessment

628

Paul Kwo, MD, AGAF, FACG, FAASLD - HBV Is Primary! Your Role in the "Call to Action" to Eliminate Viral Hepatitis By 2030

629

Robert C. Green, MD, MPH - Revisiting the Role of Genetic Testing in Patients at Risk for Late-Onset Alzheimer’s Disease: How Will the Latest Evidence and Evolving Management Paradigm Impact Treatment Decisions for Your Patients?

630

Stephanie Lee, MD, MPH - Overcoming GVHD Is the Key to Better HCT Outcomes: Guidance on Managing Acute and Chronic Disease

631

Neal K. Lakdawala, MD, Anjali Tiku Owens, MD - Loosening the Grip of Hypertrophic Cardiomyopathy: Updated Strategies for Timely Diagnosis and Disease-Modifying Treatment

632

John Ravits, MD, FAAN - Hope Is on the Horizon for Patients With ALS: Overcoming Diagnostic Difficulties and Exploring Novel Emerging Therapeutic Approaches

633

Sean Pokorney, MD, MBA - Episode 7. Marching to Their Own Rhythm: Using Consumer Wearables in AF Diagnosis and Treatment

634

Sean Pokorney, MD, MBA - Episode 6. Is That Realistic? What We’ve Learned About Anticoagulation Therapy From Real-World Studies

635

Sean Pokorney, MD, MBA - Episode 5. State-of-the-Art Treatment: Catching Up With Current Guidelines

636

Sean Pokorney, MD, MBA - Episode 4. The Fear Factor: Mitigating Patients’ Concerns About Anticoagulation

637

Sean Pokorney, MD, MBA - Episode 3. Mending the Healthcare System: Reducing Disparities

638

Sean Pokorney, MD, MBA - Episode 2. Profiles in Comorbidity: Identifying Who Is at High Risk

639

Sean Pokorney, MD, MBA - Episode 1. Looking for Trouble: The Role of Systematic Screening

640

Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP - Taking a Team-Based Approach to Moderate to Severe Psoriasis in an Era of Expanding Oral Treatment Options: Advanced Practice Clinicians as Key Partners in Care

641

Aaron T. Gerds, MD, MS / John Mascarenhas, MD - Shaping Modern Management of Myelofibrosis: Guidance on the Conjunction of Targeted Therapy and AlloHCT

642

Nicole Lamanna, MD - Building a Safety-Centric Culture in B-Cell Cancers: Interprofessional Insights on Optimizing BTKi Efficacy Through Safety Management

643

Olalekan Oluwole, MBBS, MD - The Time Is Now for Outpatient CAR-T: Essential Infrastructure, Lessons From Transplant, and New Evidence

644

Benjamin Levy, MD - Peer Pressure: How Well Do You Know Your ADCs? Answers to Key Questions About Antibody–Drug Conjugates in NSCLC

645

Benjamin M. Greenberg, MD, MHS / Jiwon Oh, MD, PhD, FRCPC - BTK Inhibition as an MS Treatment Modality: Where Do We Stand and Where Are We Headed?

646

Stephen V. Liu, MD - Perfecting Precision in Modern NSCLC Practice: Are You Optimally Integrating Biomarker-Driven Therapy?

647

Jacob Sands, MD - Facilitating Progress in the Treatment of SCLC: How to Optimize the Use of Current Systemic Options and Accelerate the Clinical Transition of Investigational Approaches

648

James M. Foran, MD, FRCPC, Jessica K. Altman, MD - The Convergence of Innovative Therapy and AlloHCT in AML: Applying Current Evidence to Improve Outcomes

649

Robert Z. Orlowski, MD, PhD - "House Rules" for Innovative Therapy in Multiple Myeloma: Guidance on Integrating Monoclonal Antibodies and BCMA and Non-BCMA Options Into Patient Care

650

Mazyar Shadman, MD, MPH, Peter A. Riedell, MD - Finding Treatment Synergy in CLL: Expert Consults on Advances With Targeted and Cellular Therapy

651

Thomas G. Martin, III, MD, Krina Patel, MD, MSc - Hitting the BCMA Target in Multiple Myeloma: Insights on CAR-T Therapy and Innovative Antibody Options

652

Matthew I. Milowsky, MD, FASCO - Fresh Perspectives on Moving Toward Personalized Care for Bladder Cancer: Tips, Tools, and Strategies for Leveraging the Latest Advancements Across the Disease Spectrum

653

Janis Taube, MD, MSc - Refining Best Practices in Cancer Immunotherapy Biomarker Testing and Pathologic Response Assessment

654

Jennifer Woyach, MD - Real-World Challenges and Solutions with BTKi in CLL: Therapeutic Insights for Community Practice

655

Prof. Mohamad Mohty, Christine N. Duncan, MD - New Rules for VOD/SOS: Modern Risk Assessment, Diagnostic Principles, and Innovative Treatment

656

Matthew R. Smith, MD, PhD - Expanding Use of Hormonal Therapeutic Strategies in Prostate Cancer: Clinical Evidence and Practical Considerations for Individualized, Patient-Centered Care

657

Sumanta Kumar Pal, MD, FASCO - Breaking New Ground in RCC Management: Expert Guidance on Leveraging Therapeutic Strategies

658

Professor Perry Elliott, MBBS, MD, FRCP, FESC, FACC - Medicine in Motion: Visual Guide to a New Generation in Care for Patients With Hypertrophic Cardiomyopathy

659

Ravin Ratan, MD, M.Ed - Addressing Key Questions About the Latest Diagnostic and Therapeutic Advances in Desmoid Tumors

660

Seth S. Martin, MD, MHS, FACC, FAHA, FASPC - Medicine in Motion: Smart Approaches for Treating HoFH

661

Marwan Sabbagh, MD, FAAN - Gearing Up for Plasma Biomarkers in the Clinic: Real-World Strategies to Facilitate the Timely and Accurate Neuropathological Diagnosis of Alzheimer’s Disease

662

Evan S. Dellon, MD, MPH - What's New in the Management of Eosinophilic Esophagitis: Working Together to Integrate Targeted Treatment Options Into Practice

663

Ghassan Abou-Alfa, MD, MBA - The HCC Revolution Continues: Exploring Evidence-Based Treatment Selection and Sequencing in Advanced Disease and Beyond

664

Vivek Subbiah, MD - Seek and You Will Find in Advanced GI Cancers: Identifying and Targeting Uncommon but Actionable Genomic Alterations in Colorectal, Pancreatic, and Other Cancers

665

Nasser Altorki, MD, Jonathan D. Spicer, MD, PhD, FRCSC - Realizing the Promise of Perioperative Immunotherapy in Resectable NSCLC: How to Modernize Best Practices Based on New Evidence and Better Multidisciplinary Alliances

666

April W. Armstrong, MD, MPH - Understanding TYK2’s Role in Psoriasis Pathogenesis and Taking a Practical Approach to Realizing Its Potential in the Clinic

667

Rachna T. Shroff, MD, FASCO - Getting Personal With Advanced BTC: Insights on Personalizing Upfront and Sequential Care With Immunotherapy and Targeted Agents

668

Jessica Donington, MD, Catherine Shu, MD - EGFR-Targeted Therapy for Early-Stage NSCLC: What Thoracic Surgeons Need to Know

669

Sanjay R. Bhagani, BSc (Hons), MB ChB, FRCP - Improving Outcomes for Hospitalized Patients with COVID-19: Expert Perspectives on Incorporating the Latest Guidelines and Evidence Into Clinical Practice

670

Shannon N. Westin, MD, MPH - New Horizons for Advanced Endometrial Cancer Treatment: Utilizing Innovative Immunotherapies and Other Novel Approaches

671

Loretta J. Nastoupil, MD - Innovation Now for Follicular Lymphoma: New Evidence for Immunotherapy, Targeted, and Chemo-Free Options

672

John C. Byrd, MD - Taking the Next Steps With Next-Generation BTK Inhibitors in CLL, MCL, and DLBCL

673

Marwan Sabbagh, MD, FAAN - Translating the Latest Research Advances Into Routine Care for Alzheimer’s Disease: Preparing Dementia Specialists With the Latest Strategies to Support Early Diagnosis and Comprehensive Care

674

Nathan A. Pennell, MD, PhD, FASCO - Fine-Tuning Biomarker Testing to Identify and Target RET Fusions as Uncommon But Actionable Genomic Alterations in NSCLC

675

Gerald Appel, MD, PhD - Targeted Complements: Exploring New Horizons Designed to Address Gaps in Treating Complement-Associated Kidney Diseases

676

Nikhil C. Munshi, MD - The Road to Remission in Multiple Myeloma: Expert Guidance on Using BCMA-Targeted Options to Enhance Clinical Outcomes

677

Prof. Hans Gelderblom, MD - New Evidence Now for Targeted Therapy in TGCT

678

Grzegorz (Greg) Nowakowski, MD - Real-World, Real Innovation in DLBCL: Perspectives on Integrating Novel Antibody Platforms Into Patient Care

679

Prof. John G. Gribben, MD, DSc - Fine-Tuning the Wave of Innovation in CLL: Personalized Models for Upfront and Sequential Care With Groundbreaking Treatment

680

Erika Hamilton, MD - Clarifying the Complexities of the Expanding Treatment Options for Advanced- and Early-Stage HR+/HER2- Breast Cancer

681

Guillermo Garcia-Manero, MD - The Future is Now in MDS: Integrating Innovative, Risk-Adapted Therapies Into Patient Management

682

Jay B. Wish, MD - Novel Strategies for Managing Patients With CKD-Associated Anemia: What Do Health-System Pharmacists Need to Know About HIF-PH Inhibitors?

683

Petros Grivas, MD, PhD / Neal D. Shore, MD, FACS - Personalizing Bladder Cancer Care in the Modern Therapeutic Era: One Size No Longer Fits All

684

Rana R. McKay, MD, Alicia K. Morgans, MD, MPH - Alicia K. Morgans, MD, MPH - Case by Case: Maximizing Personalized Approaches to Prostate Cancer

685

Steven Brem, MD - Setting Our Sights on Improved Outcomes in Glioblastoma: State-of-the-Art Care With Tumor Treating Fields and Other Innovative Approaches

686

Professor Peter Schmid, FRCP, MD, PhD - TROP2-Targeting ADCs as New Tools in the TNBC and HR+/HER2- Breast Cancer Treatment Arsenal: Advancing Patient-Centered Care to Make the Most of Modern Targeted Treatments

687

Javid Moslehi, MD - Updating Our Cardio-Oncology Skills in the Cancer Immunotherapy Era: Team-Based Strategies for Risk Assessment, Diagnosis, and Management of Myocarditis and Other Cardiac Immune-Related Adverse Events

688

Vivian Y. Shi, MD, FAAD - Hope on the Horizon for Hidradenitis Suppurativa: Leveraging Emerging Biologics to Improve Quality of Life

689

Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 8: VTE in Cancer: How Concerning Is It and What Do We Do About It?

690

Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 7: How Should VTE Be Managed in Patients With Obesity?

691

Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 6: What Is Real-World Evidence and How Is It Relevant and Important in VTE?

692

Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 5: Knocking Down Barriers in Transitions of Care

693

Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 4: How Can We Talk About VTE to Our Patients?

694

Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 3: Anticoagulation: When to Use It, With What, and for How Long?

695

Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 2: Tools for Unmasking VTE Quickly

696

Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 1: Why Are We Talking About VTE?

697

Maureen A. McMahon, MD - How I Think, How I Treat—Assessing, Managing, and Engaging Patients to Optimize Care in SLE and LN: Comparing Approaches With the Experts

698

Amit Singal, MD, MS - It Takes a Team for HCC: Improving Outcomes Through Multidisciplinary Collaboration / Modern Therapeutics

699

Sumanta Kumar Pal, MD, FASCO - RCC Clinical Consults: Making Difficult Treatment Decisions at the Intersection of the Data and the Real World

700

Javed Butler, MD, MPH, MBA - How I Think, How I Treat: Cardiology-Focused Perspectives on Using SGLT2 Inhibitors to Optimize Outcomes in Patients With Heart Failure

701

David G. Warnock, MD - The Future Looks Bright for People With Fabry Disease: Improving Diagnosis and Expanding Treatment Options

702

Catherine M. Broome, MD - Following the Diagnostic Pathway for Cold Agglutinin Disease

703

Peter H. Jones, MD, MNLA, R. Scott Wright, MD - Personalizing the Management of Hyperlipidemia: Addressing Unmet Needs Among High-Risk Patients With Atherosclerotic Cardiovascular Disease With Novel Lipid-Lowering Therapies

704

Daniel J. George, MD - Getting to the Heart of Personalized ADT for Advanced Prostate Cancer: Are You Able to Leverage New Data and Therapy Options to Maximize Cardiovascular Safety and Treatment-Related Outcomes?

705

Caron Jacobson, MD - Unlocking the Benefits of CAR-T Therapy in Hematologic Malignancies: Latest Evidence and Practical Considerations for Delivering State-of-the-Art Care

706

Jiwon Oh, MD, PhD, FRCPC - Moving Toward the Future in MS Management: What's the Latest on BTK Inhibition?

707

Erik P. Sulman, MD, PhD - Harnessing Novel Synergies With Tumor Treating Fields: Insights on Improving Survival With Multimodal Care in Aggressive Tumors

708

Sandeep K. Gupta, MD - Updates in Eosinophilic Esophagitis: Exploring Underlying Mechanisms and Integrating Novel Targeted Therapy to Improve Patient Care

709

R. Scott Wright, MD - Diagnosing and Treating Hyperlipidemia in Family Medicine: Exploring the Latest Clinical Evidence and the Role of Novel PCSK9-Targeting Therapies

710

Alicia K. Morgans, MD, MPH - Creating a Roadmap for Modern Prostate Cancer Treatment: How to Use the Most Recent Evidence on Novel Therapeutic Strategies and Shared Decision-Making to Personalize Patient Care

711

Nasser Altorki, MD - Extending Survival and Setting Our Sights on Cure in Resectable NSCLC: Getting the Details of Perioperative Immunotherapy Right

712

Morie A. Gertz, MD - Don’t Miss the Rare When Diagnosing and Treating Autoimmune Hemolytic Anemia: Focus on CAD

713

Richard K. Bogan, MD, FCCP, FAASM - Managing Disorders of Hypersomnolence: Reducing Patient Burdens, Protecting Patient Health

714

Leonard B. Bacharier, MD / Monica Kraft, MD - Selecting Targeted Treatment for Pediatric and Adult Patients With Uncontrolled, Moderate to Severe Asthma

715

Milind Desai, MD, MBA - Pushing Back Against HCM: Can Cardiac Myosin Inhibitors Alter the Disease Progression and Management Trajectory for Patients With Hypertrophic Cardiomyopathy?

716

Natasha B. Leighl, MD, MMSc, FRCPC, FASCO - Refining Biomarker Testing and Targeted Treatment of NSCLC With Common and Uncommon EGFR Mutations

717

James F. Howard Jr., MD - A Targeted Approach to Management of Generalized Myasthenia Gravis: The Latest on Novel Therapies That Improve Patient Outcomes

718

Mark W. Stolar, MD - A Call to Action for Primary Care Professionals: Your Role in Saving the Eyesight of Patients With Diabetes

719

Nicole Lamanna, MD / Deborah M. Stephens, DO - Challenges and Changes With Targeted Options in CLL: Guidance on Making Evidence-Informed Upfront and Sequential Treatment Choices

720

Praneetha Thulasi, MD, Jonathan L. Kaufman, MD - The Eye-Deal Connection in Multiple Myeloma: Establishing Ophthalmology-Oncology Relationships to Overcome Ocular Toxicity

721

Scott T. Tagawa, MD, MS, FACP - Clinical Conundrums in Pretreated Metastatic Urothelial Carcinoma: Improving Patient Outcomes With Novel Antibody-Drug Conjugates

722

Prof. Arjan Bredenoord - The Latest on New Options for Eosinophilic Esophagitis: Considering Targeted Biologic Therapy

723

Sagar Lonial, MD, FACP - Progress on the Path to Better Outcomes in RRMM: Expert Perspectives on the Further Integration of BCMA-Directed Antibodies and Cellular Therapies

724

Marina Chiara Garassino, MD - Are You Prepared for the New Wave of ADCs in NSCLC? Innovative Approaches and Practical Considerations in Targeting HER2, HER3, TROP2, and Other Alterations in Advanced Lung Cancer

725

Brendon M. Stiles, MD - Precision Decisions in Multimodal Management of Early-Stage NSCLC: Integrating EGFR-Targeted Therapy in Perioperative Settings

726

Professor Jacob P. Thyssen - Using Biologics to Manage Moderate to Severe Atopic Dermatitis: Compare Your Approach With Experts From Around the World

727

Naval Daver, MD, Amir T. Fathi, MD - The Power of Personalized Medicine in AML: Linking Individualized Treatment to Enhanced Patient Outcomes

728

Taofeek K. Owonikoko, MD, PhD - Improving Outcomes in SCLC Through Optimal Integration of the Latest Therapies: Expert Perspectives on the State of the Science, Best Practices, Multidisciplinary Care, and Future Directions

729

Sagar Lonial, MD, FACP - An "Off-the-Shelf" Approach for Myeloma Care: Visualizing the Present and Future of BCMA Antibodies

730

Sara M. Tolaney, MD, MPH - Breaking Down Barriers to Treatment Adherence and Persistence in HR+/HER2- Early Breast Cancer

731

Jay H. Shubrook, DO, FAAFP, FACOFP - Tools of the Trade: A Practical Guide to Managing NASH

732

Guillermo Garcia-Manero, MD; Gail J. Roboz, MD - The “Innovation Moment” Arrives for MDS: Guidance on Building Personalized Management Plans to Improve Patient Outcomes

733

Anju T. Peters, MD, MS - Toward a Goal of Breathing Easy: Identifying Which of Your Patients With Chronic Rhinosinusitis With Nasal Polyps Can Benefit From Targeted Biologic Therapy

734

Professor Aleix Prat, MD, PhD - Targeting HER2-Low Expression in Breast Cancer: Evaluating the Evidence, Challenges, and Opportunities for Expanding Treatment Benefit to More Patients

735

Javier Cortes, MD, PhD - SERDs at the Inflection Point in Pretreated ER+/HER2- Breast Cancer: Addressing Unmet Needs, Establishing New Standards of Care, and Improving Patient Outcomes With Novel ER-Targeting Therapies

736

Norman E. Lepor, MD, FACC, FAHA, FSCAI - Envisioning the Future of Hyperlipidemia Management: How Can We Leverage PCSK9-Targeting Therapies to Prevent Primary and Secondary Cardiovascular Events?

737

Jivianne T. Lee, MD, FACS - Room to Breathe: Leveraging Biologic Agents and Multidisciplinary Care to Optimize Management in Chronic Rhinosinusitis With Nasal Polyps

738

Steven E. Carsons, MD - Expert Perspectives on Novel Targeted Therapies for Sjögren’s Disease: Hope Is on the Horizon

739

Marcia S. Brose, MD, PhD, FASCO - Optimizing NTRK Fusion Testing and TRK Inhibition in Thyroid Cancer: Team-Based Approaches for Enhanced Outcomes

740

Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Nirav Shah, MD, MS - Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory Disease

741

Brooks D. Cash, MD, FACP, FACG, FASGE, AGAF, RFF - An Exploration of Advances in the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation in a Unique Era of Patient Care: Incorporating an Individualized Approach to Help Your Patients Find Relief

742

Sonia Glennie, ARNP, MSN, OCN, AGPCNP-BC - Moving Beyond Conventional Care for DLBCL: Oncology Nurse Leadership for the Effective and Safe Use of Innovative Antibody and Cellular Therapies

743

Jeffrey L. Neul, MD, PhD - Encouraging News in Rett Syndrome: Steps Towards a Timely, Accurate Diagnosis and Treatment Breakthroughs

744

David Staskin, MD - Controlling the Urgency Emergency, Restoring QOL: Safe and Effective Management of Overactive Bladder

745

Alexander Drilon, MD - Improving Clinical Care With Newer, Better Therapies for Targeting Actionable Gene Fusions in NSCLC

746

Sarah S. Chisolm, MD - Taking a New Look at Prurigo Nodularis: How Is Emerging Evidence Regarding Disease Pathophysiology and Treatment Influencing Patient Care?

747

Ritu Salani, MD, MBA - Harmonizing Interprofessional Care With Modern, Molecularly Informed, and Equitable Therapy for Patients With Advanced Endometrial Cancer: Lessons From a Gynecologic Cancer Center of Excellence

748

R. Sharon Chinthrajah, MD - IgE-Mediated Food Allergies: Improving Patient Quality of Life Through a Multidisciplinary Approach as a New Era of Treatment Dawns

749

Wanda Phipatanakul, MD, MS - Controlling Moderate to Severe Asthma Across the Lifespan in an Ever-Evolving Treatment Landscape: How Much Do You Know?

750

Cedric "Jamie" Rutland, MD - Addressing the Underlying Inflammation of Non–Cystic Fibrosis Bronchiectasis: Exploring Novel Treatments to Change Disease Course for Patients and Improve Quality of Life

751

Anjali Tiku Owens, MD - Going Beneath the Surface of Hypertrophic Cardiomyopathy: Understanding the Pathophysiology and Deploying New Strategies for Timely Diagnosis and Targeted Treatment

752

Robert Sidbury, MD, MPH - Can Team-Based Care and Novel Therapies Improve Outcomes in Moderate to Severe Pediatric Atopic Dermatitis?

753

Rupa R. Patel, MD, MPH, DTM&H - A Closer Look at Telehealth for PrEP: Best Practices for PrEP Delivery in a Unique Era of Care

754

Julie V. Philley, MD; Kevin Winthrop, MD, MPH - Confronting the Challenges of Nontuberculous Mycobacterial Lung Disease: Expert Strategies for Reducing Diagnostic Delays and Improving Adherence to Guideline-Based Treatment

755

Aditya Bardia, MD, MPH - Candid Conversations and Clinical Consults in Community Context: Practical Guidance for Integrating TROP2-Targeting ADCs Into Patient-Centric Breast Cancer Clinical Care

756

Beth Faiman, PhD, RN, MSN, ANP-BC, AOCN, FAAN - Reaching the Next Level of Myeloma Patient Care: Oncology Nurse Guidance on Antibody Therapy and Novel Mechanisms of Action

757

Professor Perry Elliott, MBBS, MD, FRCP, FESC, FACC - New Therapies, New Hope: Evolving Strategies for Improving Outcomes and Quality of Life in Patients With Hypertrophic Cardiomyopathy

758

Robert Z. Orlowski, MD, PhD - Building Real-World Bridges Between Clinicians and Patients With Myeloma: Guidance on Innovative Antibody Options

759

Domenica M. Rubino, MD - Getting Ahead of the Curve: Identifying and Managing Obesity in Primary Care

760

Elena Elez, MD, PhD - Realizing Improved Outcomes in HER2-Positive Gastrointestinal Cancers: New Evidence and Practical Guidance With Targeted Agents

761

Richard Beaser, MD - A Call to Action for Diabetes Specialists: Your Role in Saving the Eyesight of Patients With Diabetes

762

Prof. Carmelo Rizzari - The Path for Better Outcomes in ALL: Integrating Modern Asparaginase Compounds Into the Care of Pediatric, AYA, and Adult Patients

763

Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCL

764

Yelena Y. Janjigian, MD - Moving the Treatment of Advanced Gastroesophageal Cancers Forward: How Can We Maximize the Benefits of Novel Immunotherapy Approaches?

765

Sagar Lonial, MD, FACP - Navigating From A to B and C in Multiple Myeloma: Delivering High-Quality Care With mAbs, BCMA ADCs, and Cellular Therapy

766

Jacob Sands, MD - Assessing the Impact of Therapeutic Advances in SCLC: Instilling New Hope and Moving in Leaps and Bounds Toward Better Outcomes

767

Hussein A. Tawbi, MD, PhD - New Rules for Sequential Care in BRAF-Mutated Melanoma: Rethinking Upfront Selection and Sequencing of Immunotherapy and Targeted Agents in Metastatic Disease

768

Jason Westin, MD, MS, FACP - Rising to the Occasion: Improving Outcomes in Leukemia, Lymphoma, and Multiple Myeloma With CAR T-Cell Therapy in Community Practice

769

Michael B. Atkins, MD - Choosing Innovation With Immunotherapy in Melanoma: Guidance on Utilizing Immune-Based and Other Novel Options in Resectable and Unresectable Disease

770

Bruce Cree, MD, PhD, MAS - Re-Examining S1PR Modulation From All Angles in Relapsing Multiple Sclerosis: Impact on Physical and Cognitive Outcomes, and Practical Considerations of Long-Term Therapy

771

Leonard H. Calabrese, DO - Recognition and Management of Axial Spondyloarthritis: Best Practices for Family Medicine Physicians

772

Joan T. Merrill, MD - New Directions in Kinase Inhibition in Systemic Lupus Erythematosus: Emerging Evidence From Copenhagen

773

Anthony R. Mato, MD, MSCE - Rewriting the Treatment Script in CLL: Guidance on Integrating Modern Targeted and Next-Gen Options Into Patient Care

774

Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP - The Power of Team-Based Care and Novel Therapies in Alopecia Areata and Atopic Dermatitis: What Advanced Care Providers Need to Know

775

Prof. Dr. med. Stephan Stilgenbauer - New Rules for BTK Inhibitors in CLL: Benchmarks for Evidence-Based Treatment Selection, Sequencing, and Safety Management

776

Ashish M. Kamat, MD, MBBS - Transforming Bladder Cancer Treatment: Essential Guidance for Urologists on Therapeutic Selection, Safety, and Sequencing Along the Disease Continuum

777

Luke Maese, DO - Applying Therapeutic Innovations Against ALL: From Updated Evidence to Everyday Practice

778

Shmuel Shoham, MD - Do You Know How to Use COVID-19 Monoclonal Antibodies as Pre-Exposure Prophylaxis for Your Post-Transplant Patients? Test Your Knowledge

779

Riad Salem, MD, MBA - Making Headway Towards Better Outcomes in Intermediate- to Advanced-Stage Hepatocellular Carcinoma: A Multidisciplinary Tumor Board on Implementing Novel Locoregional and Systemic Approaches

780

Karl D. Lewis, MD - Immunotherapy Has Arrived in Advanced BCC: Collaborative Strategies for Making the Most of Novel Immune-Based Treatment

781

Nina Shah, MD - The "Myelennial" Generation: Managing the Boom of Innovative Therapy to Transform Myeloma Care and Enhance Patient Outcomes

782

Gail J. Roboz, MD - The Advantage of Innovation in AML: Guidance on Developing and Delivering Effective and Highly Personalized Care

783

Aditya Bardia, MD, MPH - Navigating the Shifting Treatment Paradigm in ER+/HER2- Breast Cancer: Harnessing Modern Treatment Options and the Expanding Evidence Base to Better Patient Care and Outcomes in Early and Advanced Disease

784

David P. Carbone, MD, PhD - Gaining an Advantage Over NSCLC: How to Achieve the Greatest Benefit With Immunotherapy From Advanced to Early Disease

785

Robert I. Haddad, MD - The Power and Promise of Immunotherapy in Head and Neck Cancer: How Established and Emerging Immune-Based Options Can Enhance Patient Care

786

Toni K. Choueiri, MD - Refining RCC Management Across the Disease Continuum: An Expert Clinical Consult on Leveraging New Evidence and Novel Therapeutic Strategies to Personalize Patient Care

787

David Alain Wohl, MD - Increasing PrEP Uptake and Confident Use for HIV Prevention in Diverse Communities

788

Benjamin M. Greenberg, MD, MHS / Professor Anthony Traboulsee, MD - Innovations and Imaging in Multiple Sclerosis: Examining the Evidence, Looking Toward the Future of Bruton Tyrosine Kinase Inhibitors

789

Richard S. Finn, MD - Setting the Course for the Optimal Management of HCC: Improving Patient Outcomes Through the Integration of Novel Therapeutic Approaches Across the Continuum of Care

790

David Weidman, MD - Therapeutic Advances in the Early Treatment of Alzheimer’s Disease: Expert Insights on Novel Biomarkers and Emerging Disease-Modifying Therapies

791

Lisa H. Lancaster, MD - The Power of Interprofessional Teams in SSc-ILD: From Diagnosis Through Management

792

Reynold A. Panettieri, Jr., MD - The Future of Severe Asthma Treatment Is Here: Expert Insights on the Rationale for Targeting Epithelial Alarmins

793

Nelson Chao, MD, MBA - Upgrading the VOD/SOS Management Tool Kit: Guidance for Effective Diagnostic Confirmation, Grading, and Treatment

794

Jeanne M. Palmer, MD - The Modern Management of Myelofibrosis: Practical Perspectives Surrounding the Use of JAK Inhibitors and Novel Therapeutics in the Peri-Transplant Setting

795

Stuart S. Winter, MD - Adapting to Innovation in Pediatric ALL: Guidance on Optimizing Modern Therapy and the Role of Novel Asparaginase Compounds

796

Zev A. Wainberg, MD - Targeting TIGIT to Extend Immunotherapy Benefits to More Cancer Patients: A Strategy to Amplify Immune Response and Enhance or Restore Antitumor Activity

797

John N. Allan, MD - Reaping the Rewards of Innovative Care in CLL: From Targeted Strategies to Cellular Therapy

798

James M. Foran, MD, FRCPC - Landmarks Across the Patient Journey in AML: Applying Evidence With Novel Therapeutics Pre- and Post-AlloHCT

799

Amber C. King, PharmD, BCOP - Making Sense of New Standards for CLL: Pharmacist Insights on Targeted Therapy and the Delivery of Team-Based Care

800

Michael R. Bishop, MD - CAR-T Cell Therapy: Are You Up to the Challenge? New Evidence and Best Practices Driving Modern Cellular Therapies as a Standard of Care for Leukemia and Lymphoma

801

Leslie Kean, MD, PhD - Overcoming the Challenges of Acute and Chronic GVHD: The Integration of Novel Therapies Into Modern Management Protocols

802

Kurt A. Schalper, MD, PhD - Decoding the Latest Evidence and Practical Recommendations on Biomarker Testing for New Therapeutic Options Targeting HER2, HER3, and TROP2 in Solid Tumors

803

Stephen V. Liu, MD - Find the Targets, Treat With Precision: Modern Principles and New Advances in Biomarker-Driven Lung Cancer Care

804

Matthew R. Smith, MD, PhD - Realizing the Potential of Novel Treatment Intensification Strategies for Metastatic Castration-Sensitive Prostate Cancer: The Experts’ Take on Key Clinical Evidence, Practical Considerations, and Best Practices for Individualized, Patient-Centered Care

805

Petros Grivas, MD, PhD - Blazing the Trail Forward in the Therapeutic Management of Bladder Cancer: Expert Insights on Incorporating the Latest Evidence and Treatment Advancements Into Practice Across the Disease Continuum

806

Kimberly A. Brown, MD, FAASLD, FAST, AGAF - Refractory Ascites and Esophageal Variceal Hemorrhage: Practical Guidance to Improve Patient Outcomes

807

Bruce R. Korf, MD, PhD - Revolutionizing the Standard of NF1 Care: Insights on Innovative MEK-Inhibitor Options for NF1-Associated PNs

808

Nancy P. Moldawer, RN, MSN - Aligning Nursing Care Strategies With Evolving Patient Needs in RCC: Interprofessional Insights on Optimizing Outcomes With Novel Targeted and Immune-Based Therapies

809

Nasser Altorki, MD - How to Integrate Perioperative Immunotherapy Into Multimodal Treatment Plans to Improve Outcomes in Resectable NSCLC

810

Ashish M. Kamat, MD, MBBS - Multidisciplinary Guidance on Translating the Latest Therapeutic Advances Into Patient Care for Early to Advanced Bladder Cancer: Clinical Consults and Cases From the Community

811

April W. Armstrong, MD, MPH / Kenneth B. Gordon, MD - Fine-Tuning the JAK/STAT Pathway in Psoriasis: Safely Targeting the Underlying Mechanisms of Disease With TYK2 Inhibition

812

Amy Goodrich, CRNP - Hope Is Here in CLL: Oncology Nurse Strategies for Delivering Effective, Compassionate, and Modern Care to Patients

813

Prof. Solange Peters, MD, PhD - Parsing the Practicalities of Pathologic Response Assessment After Neoadjuvant Immunotherapy to Facilitate Progress in Early-Stage Cancers

814

Linda Ahn, MSN, ANP-BC, AOCNP - Tackling the Practicalities of Antibody–Drug Conjugate Therapy for Solid Tumors: Improving Clinical Care With HER2-, HER3-, and TROP2-Targeted Therapies

815

Liana G. Apostolova, MS, MD, FAAN - Accelerating Progress in the Treatment of Alzheimer’s Disease: How Can We Achieve Timely and Accurate Neuropathological Diagnosis and Precision Management of Mild Cognitive Impairment in Early Alzheimer’s Disease?

816

Bruce Cree, MD, PhD, MAS - Leveraging the Power of Anti-CD20 mAbs in Patient-Centric Multiple Sclerosis Care

817

Jonathan Corren, MD - Airway Inflammation Isn’t the Only Problem: Shining a Light on the Role of Airway Hyper-Responsiveness in Severe Asthma

818

Brett King, MD, PhD - Addressing Healthcare Disparities and Optimizing Patient Outcomes in Atopic Dermatitis and Alopecia Areata: Expert Insight on How to Improve Access and Quality of Care

819

Rajiv Agarwal, MD, MS - A Renewed Look at MRA Therapy: Improving Renal Outcomes and Reducing Risks in Patients With Type 2 Diabetes

820

Sarina Elmariah, MD, PhD, MPH - Addressing the Burden of Prurigo Nodularis: Expert Insight on Disease Pathogenesis and the Clinical Potential of Novel Therapeutic Options

821

Anthony Martinez, MD, AAHIVS, FAASLD - Sharing the Cure: Best Practices for Primary Care Providers to Improve HCV Prevention, Care, and Treatment

822

Kurt A. Schalper, MD, PhD - Progress and Practicalities in Immunotherapy Biomarker Testing and Pathologic Response Assessment in Solid Tumors: What’s New and What You Need to Know and Do

823

Mark A. Socinski, MD - Expanding Options, Lingering Questions: How to Select the Right Immunotherapy for First-Line Treatment of Advanced NSCLC

824

Joe R. Anderson, PharmD, PhC - Taking the Pulse of Undiagnosed Atrial Fibrillation: Pharmacists as a Lynchpin of Detection and Team-Based Care

825

Joseph Diaz, MD- Advances in Chronic Spontaneous Urticaria: Expert Insight on Translating Progress to Practice for Improved Symptom Control and Quality of Life

826

Erika Hamilton, MD - How to Harness Adjuvant CDK4 and 6 Inhibition to Prevent Recurrences in High-Risk HR+/HER2- Early Breast Cancer: New Goals and Better Tools to Close the Gaps

827

Professor Andrew Menzies-Gow - Tackling the Challenge of Treating Severe Asthma: Taking Aim at the Airway Epithelium

828

Henry M. Kuerer, MD, PhD, FACS - Expanding the Benefits of PARP Inhibitor Therapy to More Patients With Breast Cancer and Earlier Disease Settings: Multidisciplinary Perspectives on How to Maximize the Potential of PARP Inhibitors and Optimize Their Use as Part of Multimodal Management of Breast Cancer

829

Jacob Sands, MD - Weighing the Evidence, Parsing the Practicalities: Integrating New Treatment Options Into the SCLC Treatment Arsenal to Improve Patient Outcomes in Oncology Practice

830

Lucia M. Novak, MSN, ANP-BC, BC-ADM - Building Skills for Clinical Practice: Optimizing Insulin Management and Personalizing Diabetes Care With Faster-Acting Formulations and Newer Options in Delivery Technology

831

Nina Shah, MD - Mapping the Therapeutic Odyssey in Multiple Myeloma: Interprofessional Guidance on Evidence-Based Treatment Selection and Sequencing

832

Bhavana Pothuri, MD, MS - Expanding the Benefits and Refining the Role of Immune Checkpoint Inhibitors in the Treatment of Recurrent and Advanced Endometrial Cancer

833

Elizabeth Eaman, MD - Cancer Screening and Preventive Care for Transgender Individuals: Patient and Provider Perspectives on Best Practices and Special Considerations

834

Anjay Rastogi, MD - Making the Case for Preventing and Managing Nephropathy in Patients With Fabry Disease

835

Michael E. Wechsler, MD - How I Think, How I Treat—Assessing, Managing, and Engaging Patients With Uncontrolled, Moderate to Severe Asthma: Comparing Approaches With Experts Around the World

836

Javier Morales, MD, FACP, FACE - Is Synergism the Secret to Success? Candid Conversations on Targeting GIP and GLP-1 to Individualize Treatment in Patients With T2DM and Obesity

837

John J. Russell, MD - Cancer Control Through Early Blood-Based Detection: Perspectives on Integrating Innovative Multicancer Early Detection Tests in the Primary Care Setting

838

Milind Desai, MD, MBA - New Evidence on Cardiac Myosin Inhibition in Hypertrophic Cardiomyopathy: Analysis From Washington, DC

839

Tanios Bekaii-Saab, MD - Dialing in the Dose: Reviewing Recent Evidence and Team-Based Strategies to Personalize and Optimize Patient Care in Metastatic Colorectal Cancer

840

Bradley J. Monk, MD, FACS, FACOG - When Are PARP Inhibitors the Best Choice for Patients With Ovarian Cancer? Personalizing Therapeutic Selection Across the Disease Continuum

841

Anthony R. Mato, MD, MSCE - Solving the Challenge of Tumor Lysis Syndrome: Expert Insight and Guidance on a Challenging Oncologic Emergency

842

Kristina M. Deligiannidis, MD - Applying Evidence to Practice in Postpartum Depression: Expert Guidance on Integrating Therapeutic Innovations and Shared Decision-Making Strategies to Optimize Patient Care

843

Anita H. Clayton, MD - Recent Advances in the Management of Depressive Disorders: Preparing for a Shift in the Treatment Paradigm

844

Pasi A. Jänne, MD, PhD - Addressing Key Targets in Advanced NSCLC: Evaluating the Latest Evidence and Clinical Opportunities for HER2-, HER3-, and TROP2-Targeted Therapies

845

Geoffrey Barnes, MD, MSc - Primary Care Call to Action for VTE Management: Sharpening Skills in Recognition, Treatment, and Secondary Prevention

846

Sumanta Kumar Pal, MD, FASCO - Navigating Evolving Standards of Care in Renal Cell Carcinoma: Expert Insights on Selecting and Sequencing Targeted and Immunotherapy Options and a Look at Emerging Strategies

847

Gregory W. Albers, MD / S. Claiborne “Clay” Johnston, MD, PhD - Mastering the Use of Dual Antiplatelet Therapy for Preventing Recurrent Stroke: How Well Do Your Current Strategies Match With the Experts?

848

Julie Parsons, MD - Breakthroughs in Spinal Muscular Atrophy: Managing the Life-Changing Impact of Gene Replacement Therapy

849

Henry M. Kuerer, MD, PhD, FACS / Heather L. McArthur, MD, MPH - Translating Progress With Immunotherapies and Targeted Agents Into Improved Outcomes in Triple-Negative Breast Cancer: Surgical and Clinical Perspectives on Modern Multimodal Treatment Approaches

850

Carla M. Nester, MD, MSA, FASN - Hope Is on the Horizon: The Clinical Potential of Emerging Disease-Modifying Therapies for Managing Complement 3 Glomerulopathy

851

Milind Javle, MD - Embracing the Era of Individualized Therapy in Advanced Biliary Cancers: Expert Strategies for Applying New and Emerging Targeted Treatment Options Through Precision Medicine

852

Cindy Neunert, MD, MSCS - Modern Management of ITP: Thinking Beyond the Conventional Therapies

853

Petros Grivas, MD, PhD - Achieving State-of-the-Art Care in Bladder Cancer in an Era of Innovative Therapeutic Solutions

854

J. Fernando Arevalo - Seeing Eye to Eye: Improving Outcomes Among Rural Spanish-Speaking Latinx Patients With Diabetic Retinopathy or Diabetic Macular Edema

855

Amit Bar-Or, MD, FRCPC / Daniel S. Reich, MD, PhD - Rationale, Evidence, and Practical Potential for BTK Inhibitors in Patient-Centered MS Care: Where We Stand Now

856

John B. Buse, MD, PhD - Complementary Actions All Around: Lowering Cardiometabolic Risks While Achieving Glycemic Targets With GLP-1 RAs

857

Nasser Altorki, MD / Jonathan D. Spicer, MD, PhD, FRCSC - Can the Addition of Immunotherapy to Multimodal Management of Stage I-III NSCLC Help Break the Stalled Cycle of Poor Outcomes?

858

Jennifer Wargo, MD, MMSc - Linking Immunotherapy to Better Outcomes in Resectable Melanoma: Guidance on Integrating Immune-Based Adjuvant and Neoadjuvant Options

859

Purvi S. Parikh, MD, FACP, FACAAI / Cedric ""Jamie"" Rutland, MD - Taking It From the Top: Targeting a New Approach to Controlling Severe Asthma

860

Stephen V. Liu, MD - Visual Exploration of the Possibilities for Macrocyclic TKIs in Treatment-Naïve and Pretreated Fusion-Positive NSCLC and Other Tumors

861

Robert Dreicer, MD, MS, MACP, FASCO - Decisions and Dilemmas in Prostate Cancer Management: Building on Progress to Advance Personalized Care Through Candid Conversations and Expert Clinical Consults

862

Mark S. Freedman, MD - Leveraging S1PR Modulators to Provide Patient-Centered MS Care: An Expert-Driven Review of the Data

863

Richard S. Finn, MD - Mapping the Optimal Treatment Route in HCC: Identifying Best Practices in an Expanding Therapeutic Landscape

864

Boris Sepesi, MD / Tina Cascone, MD, PhD - Bringing Precision Oncology to Early-Stage Lung Cancer, With Adjuvant EGFR-Targeted Therapy Leading the Way: What Thoracic Surgeons Need to Know and Do

865

Anthony R. Mato - The Rising Tide of Novel BTK Inhibitors: Case-Based Guidance on Overcoming Intolerance, Resistance, and Other Clinical Challenges in B-Cell Cancers

866

Sam Cheng, MD / Angela Pham, MD - Short Bowel Syndrome IMPACT Initiative: An Initiative to Individualize Treatment and Improve the Pediatric to Adult Healthcare Transition

867

Tammie L.S. Benzinger - The Expanding Role of Neuroimaging in Alzheimer’s Disease Diagnosis and Management: Is Radiology Prepared for New Challenges?

868

Paneez Khoury - Easing the Burden of Hypereosinophilic Syndrome: An Animated Exploration of the Role of Targeted Therapy to Improve Patient Outcomes

869

Alan "Tony" Amberg - Addressing Unmet Needs in the Management of Schizophrenia and Bipolar Disorder: New and Emerging Therapeutic Options to Enhance Treatment and Maximize Patient Outcomes

870

Michael Heinrich, MD - Optimally Sequencing Modern TKIs in GIST: Expert Perspectives From an Interprofessional Sarcoma Team

871

William D. Tap, MD - Practice Points in TGCT: Updates on Safe Use of Novel Systemic Options

872

Christian B. Ramers, MD, MPH, AAHIVS - A Closer Look at Telehealth for HIV: Best Practices for Patient Management in a Unique Era of Care

873

Professor Thomas Powles, MBBS, MRCP, MD - Carrying Through in Advanced/Metastatic Urothelial Carcinoma: Expert Perspectives on Recent Practice‐Changing Data and the Practicalities of Individualizing and Continuing Care With Novel Immunotherapy Maintenance Strategies

874

Suzanne Lentzsch, MD, PhD - A Is for Antibody in Multiple Myeloma: Practical Insights and Patient Voices Along the Therapeutic Journey

875

Carlos M. de Castro, MD - Upstream and Downstream Targeting of the Complement Pathway to Manage PNH: Current and Emerging Inhibitors

876

Grzegorz (Greg) Nowakowski, MD - Taking the Turn to Treatment Innovation in DLBCL: Real-World Insight on Integrating Antibodies and Cellular Therapy Into Patient Care

877

Anita H. Clayton, MD - Recent Advances and Novel Options in Depression: Reviewing the Evidence for GABA-Modulating Neuroactive Steroids for Major Depressive Disorder

878

George L. Bakris, MD / Joanna Hudson, PharmD, BCPS, FASN, FCCP, FNKF - Advancing the Standard of Care for Patients with Hyperkalemia: Insights and Evidence for Clinical Pharmacy Practice

879

Sara M. Tolaney, MD, MPH - New Advances and Opportunities for Improvement in HR+/HER2- Early Breast Cancer: Practical Strategies for Optimal Clinical Integration of Adjuvant CDK4 and 6 Inhibitor Therapy

880

Biree Andemariam, MD - The Evolution of Sickle Cell Disease: Current Advances and Future Possibilities

881

Lorinda Chung, MD, MS - Covering All the Bases in SSc-ILD Care: Expert Strategies for Diagnosis, Treatment, and Managing Comorbidities

882

Chris A. Liacouras, MD - Expert Perspectives on Improving Early Recognition of Eosinophilic Esophagitis and Examining the Potential Clinical Utility of Emerging Targeted Therapy

883

Erika Hamilton, MD - Expanding Treatment Options in ER+/HER2- Breast Cancer: Expert Perspectives on the Rapidly Emerging Role of SERDs, SERMs, and SERCAs, and the Practical Considerations of Leveraging Established and Innovative Therapies

884

Nathan H. Fowler, MD - A Better Blend for Follicular Lymphoma: How Targeted, Epigenetic, and Immune Therapies Are Changing Patient Care

885

Steven Brem, MD - A New Wave of Progress in Glioblastoma: Expert Guidance on Delivering Modern Personalized Care With Tumor Treating Fields and Novel Systemic Approaches

886

Neal K. Lakdawala, MD - Making New Strides in Hypertrophic Cardiomyopathy: The Latest Guidelines, Science, and Strategies for Early Diagnosis and Tailored Treatment

887

Stephen R. Broderick, MD, MPHS/Heather A. Wakelee, MD - Has Immunotherapy Brought Us to an Inflection Point in the Multimodal Management of Stage I-III NSCLC? Dissecting the Data and Instituting Multidisciplinary Alliances to Improve Outcomes in Early-Stage Disease

888

Christopher Baugh, MD, MBA & Mark M. Awad, MD, PhD - Maintaining Vigilance to Mitigate Cancer Immunotherapy-Related Toxicities in the Emergency Department: Be Aware, Stay Alert, and Change Your Practice

889

John C. Byrd, MD - Customizing Care in CLL With BTK Inhibitors: Evidence and Applications for Therapy Selection, Sequencing, and Safety Management

890

Bradley S. Miller, MD, PhD - Advances in Pediatric Growth Hormone Therapy: Visualizing the Impact on Individualized Care

891

John G. Gribben, MD, DSc, FRCP, FRCPath, FMedSci - Achieving Innovation in CLL Care: Evidence-Informed Choices With Targeted Options and Next Steps in Disease Management

892

Jennifer Wargo, MD, MMSc - Leveraging Neoadjuvant and Adjuvant Immunotherapy to Break Through the Outcomes Plateau, Prevent Recurrences, and Improve Curability in Early-Stage Cancers

893

Lenard A. Adler, MD / Oren Mason, MD - Overcoming Challenges in the Recognition and Management of Adult ADHD in Primary Care: Optimizing Outcomes to Reduce Disease Burden and Improve Quality of Life

894

Robert Dreicer, MD, MS, MACP, FASCO/Pedro C. Barata, MD, MSc - Personalizing and Advancing Modern Treatment Approaches to Prostate Cancer

895

Emma Guttman-Yassky, MD, PhD - Expert Insights From Around the Globe on Tailoring Treatment for Patients With Atopic Dermatitis

896

Petros Grivas, MD, PhD - Breaking Down the Evidence in Bladder Cancer: Expert Perspectives and Practical Strategies on Immune, Targeted, and Antibody-Based Therapies

897

David Malebranche, MD, MPH - Parallel Perspectives: A Unique Look at HIV Treatment Decisions From the Provider and the Patient

898

Sumanta Kumar Pal, MD, FASCO - Selecting and Sequencing Targeted and Immunotherapy Regimens for RCC: How Will the Latest Evidence Impact Treatment Decisions for My Patients?

899

Evan S. Dellon, MD, MPH - Fulfilling a Need in the Management of Patients With Eosinophilic Esophagitis: An Exploration of Novel and Emerging Therapeutic Options

900

Amit Singal, MD, MS - Harmonizing HCC Care With a Multidisciplinary Ensemble: Guidance for the Era of Novel Locoregional, Multimodal, and Systemic Strategies

901

David R. Jones, MD - Adjuvant EGFR-Targeted Therapy as a Game Changer: How to Implement New Standards of Care in Multimodal Management of Stage I-III EGFR-Mutated NSCLC

902

Javid Moslehi, MD - Improving the Detection and Management of Cardiac Immune-Related Adverse Events in Patients With Cancer Is a Must: Are You Prepared?

903

Joyce O’Shaughnessy, MD - Raising the Bar in HR+/HER2- Early Breast Cancer: Multidisciplinary Strategies for Integrating the CDK4 and 6 Inhibitors

904

Steven E. Carsons, MD - Addressing Unmet Needs in the Treatment of Primary Sjögren's Syndrome: Expert Insight on the Therapeutic Potential for CD40 Pathway Blockade

905

Domenica M. Rubino, MD & Donna H. Ryan, MD, FTOS -Gut Feeling: The Increasing Importance of GLP-1–Based Therapies for Personalized Obesity Management

906

Jubilee Brown, MD - Changing Tides in Advanced Endometrial Cancer: A Visual Exploration of Current and Emerging Strategies to Maximize the Potential of Cancer Immunotherapies

907

Nirav Shah, MD, MS - Visualizing Progress With BTK Inhibitors: An Animated Journey Through the Mechanisms of Covalent and Noncovalent Options

908

R. Sharon Chinthrajah, MD - Fulfilling Unmet Treatment Needs for Patients With IgE-Mediated Food Allergies: An Animated Exploration of Emerging Targeted Therapy

909

Erik P. Sulman, MD, PhD - Implementing Synergistic Multimodal Approaches With Tumor Treating Fields to Extend Survival in Aggressive Cancers

910

Lynette M. Sholl, MD - Time for Even More Precision in Testing and Treatment of EGFR-Mutated NSCLC: Refining and Expanding Best Practices in Advanced and Early-Stage Disease Settings

911

Benjamin M. Greenberg, MD, MHS & Professor Anthony Traboulsee, MD - Bruton Tyrosine Kinase Inhibitors for MS: Progress in the Development of an Emerging Therapeutic Approach

912

Donna E. Sweet, MD, AAHIVS, MACP - The HIV Prevention–Certified Provider Program: A Training and Certificate Program Designed to Improve Competencies and Expand the HIV Prevention Workforce

913

Richard Elion, MD / Rupa R. Patel, MD, MPH, DTM&H - PrEP for All Ages: A Comprehensive Look at Employing HIV Prevention Strategies Across All Age Groups

914

Jonathan W. Goldman, MD - Translating Science, Transforming Practice, and Making Headway Toward Better Outcomes in SCLC: Immunotherapy Has Changed the Game, but Where Do We Go Next?

915

Carl Regillo, MD - Clinical Colloquia in Retinal Disease: Updating Evidence-Based, Patient-Centered Care for Diabetic Retinopathy

916

Ikuo Hirano, MD - On the Cusp of a New Era in Treatment for Eosinophilic Esophagitis: Expert Insights on the Latest Advances in Targeted Therapy

917

Bruce Cree, MD, PhD, MAS - Exploring the Convergence of Advances in S1P Receptor Modulation With Progress in Understanding Brain Atrophy and Cognition Measures in Multiple Sclerosis

918

Jonathan A. Bernstein, MD - Visualizing Progress in the Management of Chronic Spontaneous Urticaria: Harnessing the Clinical Potential of New and Novel Therapies to Address Unmet Patient Needs

919

Prof Eric Van Cutsem, MD, PhD - Putting a Personalized Colorectal Cancer Treatment Algorithm Into Practice: Navigating Practicalities in the Era of Molecularly Defined Care

920

Timothy Berger, MD - Changing the Game for Patients With Prurigo Nodularis: Best Practices to Achieve Treatment Goals and Improve Quality of Life

921

Andrew J. Wagner, MD, PhD - Overcoming the Challenges of Diverse TGCT Presentations: Diagnostic and Treatment Principles for the Multidisciplinary Team

922

Kurt A. Schalper, MD, PhD - Evolving Standards in Biomarker Testing, Scoring, and Results Interpretation Driven by the Broadening Role of Cancer Immunotherapy

923

Lisa A. Beck, MD - Integrating the Latest Evidence Into Practice: Expert Insights on Targeted Biologic Therapy for Pediatric and Adult Patients With Moderate to Severe Atopic Dermatitis

924

Professor Dame Pamela J. Shaw - On the Cusp of a New Targeted Treatment Era in ALS: Exploring the Emerging Therapeutic Landscape

925

Peter A. Kouides, MD - Advancing Treatment of von Willebrand Disease: A Visual Exploration on Personalizing Care With Current and Emerging Management Strategies

926

Philip J. Mease, MD, MACR - Improving the Recognition and Effective Management of Axial Spondyloarthritis: Practical Guidance for the Primary Care Provider

927

Srdan Verstovsek, MD, PhD / Ruben A. Mesa, MD, FACP - Understanding the Clinical Spectrum of Myelofibrosis: Expert Perspectives on Molecular Biology, JAK Inhibitors, and Emerging Therapeutics

928

Melissa L. Johnson, MD - Harnessing the Potential of HER2-, HER3-, and TROP2-Targeted Therapies to Address Unmet Needs in Advanced NSCLC

929

Daniel Jacoby, MD - Easing the Burden of Hypertrophic Cardiomyopathy: Progress in Understanding and Addressing Its Pathophysiology

930

Nicole Lamanna, MD / Jennifer Woyach, MD - Seizing the Day With BTK Inhibitors in CLL: Evidence-Informed Therapy Selection, Safety, and Sequential Care

931

Anthony R. Mato, MD, MSCE - Interprofessional Perspectives on Safety Management With Targeted Therapy for B-Cell Malignancies

932

Sagar Lonial, MD, FACP - Breaking Therapeutic Barriers in RRMM: Team-Based Solutions for Integrating Novel Antibody Platforms and Improving Myeloma Care

933

Jared Weiss, MD - Raising the Bar for Patient Outcomes With Transcription Inhibition and Other New Options in the Treatment Arsenal for SCLC: Rationale, Mechanisms of Action, Latest Data, and Practicalities of Clinical Use in Oncology Practice

934

Milind Javle, MD - Taking Action in Advanced Biliary Cancers: Expert Insights on Integrating Newly Available and Innovative Therapeutics to Deliver Precision-Based Care

935

Ian Pavord, FMedSci - Across the Age Spectrum: Expert Insights on Emerging Uses of Targeted Therapy for the Treatment of Uncontrolled Moderate to Severe Asthma

936

Kenneth R. Cooke, MD - Collaborative Strategies for Managing VOD/SOS: Interprofessional Insights on Advances in Diagnosis, Severity Grading, and Treatment

937

Anthony R. Mato, MD, MSCE - The Next Building Block for B-Cell Cancer Care: Exploring Personalized Treatment With Emerging BTK Inhibitor Options in CLL/SLL and MCL

938

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA/ Kathryn Maples, PharmD, BCOP / Tim J. Peterson, PharmD, BCOP -Making Sense of the New World of Myeloma Care: Pharmacy Perspectives on Novel Antibodies and BCMA CAR-T Therapy

939

Stephen V. Liu, MD - Maximizing the Potential of Immunotherapy in Multimodal Management of Unresectable Stage III NSCLC: Collaboration Is Crucial, Patient Selection Is Paramount, Close Monitoring Is Critical

940

Sanam Loghavi, MD - Secondary AML Through the Microscope: A Pathology-Informed Guide to Modern Diagnostic and Treatment Principles

941

April W. Armstrong, MD, MPH / Kenneth B. Gordon, MD - Taking Aim at the TYK2 Pathway in Psoriasis: Addressing Unmet Treatment and Patient Needs With an Innovative Therapeutic Approach

942

Jamie E. Chaft, MD - Marking New Milestones With Immunotherapy in Locally Advanced and Early Lung Cancer: Latest Data Informing Best Practices for Multimodal Management of Stage I-III NSCLC

943

Stephen V. Liu, MD - Tracking All the Targets in Genomically Altered NSCLC: Everything You Need to Know About Biomarker Testing and Treatment

944

Nina Shah, MD - Innovation at Warp Speed for Multiple Myeloma: Tumor Board Insights on State-of-the-Art Care

945

Gail J. Roboz, MD - Clinical Consults on Modern AML Therapy: Where Precision Care Meets Potent Therapeutics

946

Peter A. Lio, MD - Overcoming Challenges in the Management of Moderate to Severe Atopic Dermatitis: Practical Strategies for Selecting Treatment for Pediatric and Adult Patients

947

Manish A. Shah, MD, FASCO - Redrawing the Algorithm in Gastric and GEJ Cancers: Treatment Planning and Sequencing in the Era of Immunotherapy

948

Ian W. Flinn, MD, PhD - Visualizing the Present and Future of CLL: How Innovative Therapies and State-of-the-Art Combinations Are Transforming Patient Care

949

Laura J. Zitella, MS, RN, ACNP-BC, AOCN - Taking the Fight to AML: Oncology Nurse Perspectives, Principles, and Practice in an Era of Innovative Therapies

950

Alok A. Khorana, MD, FACP, FASCO / Robert D. McBane, II, MD - Reducing the Global Burden of Cancer-Associated VTE: Applying Guideline-Concordant, Evidence-Based Care and Shared Decision-Making Strategies to Improve Patient Outcomes